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A B S T R A C T
Background
Prior to introducing pneumococcal conjugate vaccines (PCVs), Streptococcus pneumoniae was most commonly isolated from middle ear
fluid of children with acute otitis media (AOM). Reducing nasopharyngeal colonisation of this bacterium by PCVsmay lead to a decline
in AOM. The effects of PCVs deserve ongoing monitoring since studies from the post-PCV era report a shift in causative otopathogens
towards non-vaccine serotypes and other bacteria. This updated Cochrane Review was first published in 2002 and updated in 2004,
2009, and 2014. The review title was changed (to include the population, i.e. children) for this update.
Objectives
To assess the effect of PCVs in preventing AOM in children up to 12 years of age.
Search methods
We searched CENTRAL, MEDLINE, Embase, CINAHL, LILACS, Web of Science, and trials registers (ClinicalTrials.gov and WHO
ICTRP) to 29 March 2019.
Selection criteria
Randomised controlled trials of PCV versus placebo or control vaccine.
Data collection and analysis
We used the standard methodological procedures expected by Cochrane. The primary outcomes were frequency of all-cause AOM and
adverse effects. Secondary outcomes included frequency of pneumococcal AOM and frequency of recurrent AOM (defined as three or
more AOM episodes in six months or four or more in one year). We used GRADE to assess the quality of the evidence.
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Main results
We included 14 publications of 11 trials (60,733 children, range 74 to 37,868 per trial) of 7- to 11-valent PCVs versus control vaccines
(meningococcus type C vaccine in three trials, and hepatitis A or B vaccine in eight trials). We included two additional trials for this
update. We did not find any relevant trials with the newer 13-valent PCV. Most studies were funded by pharmaceutical companies.
Overall, risk of bias was low. In seven trials (59,415 children) PCVs were administered in early infancy, while four trials (1318 children)
included children aged one year and over who were either healthy or had a history of respiratory illness. There was considerable clinical
heterogeneity across studies, therefore we did not perform meta-analyses.
Adverse events
Nine trials reported on adverse effects (77,389 children; high-quality evidence). Mild local reactions and fever were common in both
groups, and occurred more frequently in PCV than in control vaccine groups: redness (< 2.5 cm): 5% to 20% versus 0% to 16%;
swelling (< 2.5 cm): 5% to 12% versus 0% to 8%; and fever (< 39 °C): 15% to 44% versus 8% to 25%. More severe redness (> 2.5
cm), swelling (> 2.5 cm), and fever (> 39 °C) occurred less frequently (0% to 0.9%, 0.1% to 1.3%, and 0.4% to 2.5%, respectively
in children receiving PCV) and did not differ significantly between PCV and control vaccine groups. Pain or tenderness, or both was
reported more frequently in PCV than in control vaccine groups: 3% to 38% versus 0% to 8%. Serious adverse events judged causally
related to vaccination were rare and did not differ significantly between groups, and no fatal serious adverse event judged causally related
to vaccination was reported.
PCV administered in early infancy
PCV7
The effect of a licenced 7-valent PCV with CRM197 as carrier protein (CRM197-PCV7) on all-cause AOM varied from −5% (95%
confidence interval (CI) −25% to 12%) relative risk reduction (RRR) in high-risk infants (1 trial; 944 children; moderate-quality
evidence) to 6% (95% CI −4% to 16%; 1 trial; 1662 children) and 6% (95% CI 4% to 9%; 1 trial; 37,868 children) RRR in low-
risk infants (high-quality evidence). PCV7 with the outer membrane protein complex of Neisseria meningitidis serogroup B as carrier
protein (OMPC-PCV7), was not associated with a reduction in all-cause AOM (RRR −1%, 95% CI −12% to 10%; 1 trial; 1666
children; high-quality evidence).
CRM197-PCV7 and OMPC-PCV7 were associated with 20% (95% CI 7% to 31%) and 25% (95% CI 11% to 37%) RRR in
pneumococcal AOM, respectively (2 trials; 3328 children; high-quality evidence) and CRM197-PCV7 with 9% (95% CI −12% to
27%) to 10% (95% CI 7% to 13%) RRR in recurrent AOM (2 trials; 39,530 children; high-quality evidence).
PHiD-CV10/11
The effect of a licenced 10-valent PCV conjugated to protein D, a surface lipoprotein of Haemophilus influenzae, (PHiD-CV10) on
all-cause AOM varied from 6% (95% CI −6% to 17%; 1 trial; 5095 children) to 15% (95% CI −1% to 28%; 1 trial; 7359 children)
RRR in healthy infants (moderate-quality evidence). PHiD-CV11 was associated with 34% (95% CI 21% to 44%) RRR in all-cause
AOM (1 trial; 4968 children; high-quality evidence).
PHiD-CV10andPHiD-CV11were associatedwith 53%(95%CI 16%to 74%) and52%(95%CI37%to 63%)RRR in pneumococcal
AOM (2 trials; 12,327 children; high-quality evidence) and PHiD-CV11 with 56% (95% CI −2% to 80%) RRR in recurrent AOM
(1 trial; 4968 children; moderate-quality evidence).
PCV administered at later age
PCV7
We found no evidence of a beneficial effect on all-cause AOM of administering CRM197-PCV7 in children aged 1 to 7 years with a
history of respiratory illness or frequent AOM (2 trials; 457 children; high-quality evidence) and CRM197-PCV7 combined with a
trivalent influenza vaccine in children aged 18 to 72 months with a history of respiratory tract infections (1 trial; 597 children; high-
quality evidence).
CRM197-PCV9
In 1 trial including 264 healthy day-care attendees aged 1 to 3 years, CRM197-PCV9 was associated with 17% (95% CI −2% to
33%) RRR in parent-reported all-cause OM (low-quality evidence).
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Authors’ conclusions
Administration of the licenced CRM197-PCV7 and PHiD-CV10 during early infancy is associated with large relative risk reductions
in pneumococcal AOM. However, the effects of these vaccines on all-cause AOM is far more uncertain. We found no evidence of a
beneficial effect on all-cause AOM of administering PCVs in high-risk infants, after early infancy (i.e. in children one year and above),
and in older children with a history of respiratory illness. Compared to control vaccines, PCVs were associated with an increase in
mild local reactions (redness, swelling), fever, and pain and/or tenderness. We found no evidence of a difference in more severe local
reactions, fever, or serious adverse events judged causally related to vaccination.
P L A I N L A N G U A G E S U M M A R Y
Pneumococcal vaccination for preventing acute middle ear infections in children
Review question
We reviewed the evidence about the effect of vaccination against Streptococcus pneumoniae (pneumococcus, a type of bacterium) for
preventing acute middle ear infections in children.
Background
Before nationwide implementation of vaccination against Streptococcus pneumoniae with pneumococcal conjugate vaccines (PCVs),
pneumococcus was the most frequent cause of acute middle ear infections in children. Vaccination against this bacterium with PCVs
may therefore lead to fewer acute middle ear infections in children. However, ongoing monitoring of the effects of PCVs on acute middle
ear infections is warranted since recent studies report a shift in bacteria causing acute middle ear infections towards pneumococcal types
not included in the vaccines and other bacteria.
Study characteristics
The evidence is current up to 29 March 2019. We included 11 trials of PCVs versus control vaccines (meningococcus type C conjugate
vaccine in three trials, and hepatitis A or B vaccine in eight trials) involving a total of 60,733 children. The PCVs used in the trials
contained 7 to 11 different types of pneumococcus. None of the trials used the newer PCV containing 13 different types. Most trials
were funded by pharmaceutical companies. Overall, risk of bias was low. In seven trials (59,415 children), children received PCVs in
early infancy, and four trials included 1318 children aged one year and over who were either healthy or who had previous respiratory
illness or frequent acute middle ear infections.
Key results
When a licenced vaccine containing seven different types of pneumococcus (CRM197-PCV7) was given during early infancy, the risk
of experiencing acute middle ear infections either increased by 5% in high-risk infants or decreased by 6% in low-risk infants. When
administrating a licenced vaccine containing 10 types of pneumococcus together with a carrier protein from another bacterium called
Haemophilus influenzae (PHiD-CV10), the risk of experiencing acute middle ear infections decreased by 6% to 15%, however neither
of these estimates reached significance.
Giving PCV7 after early infancy (to children aged one year and above), and in older children with a history of respiratory illness or
frequent acute middle ear infections, was not associated with reductions in acute middle ear infections.
Mild local reactions (redness, swelling), fever, and pain/tenderness were common and occurred more frequently in children receiving
PCV than in those receiving control vaccines. More severe local reactions (redness and swelling > 2.5 cm) and fever (> 39 °C) occurred
far less frequently and did not differ between vaccine groups. Serious adverse events judged causally related to vaccination were rare
and did not differ significantly between vaccine groups.
Quality of the evidence
We assessed the quality of the evidence for PCV7 in early infancy to be high (further research is very unlikely to change our confidence
in the estimate of effect). We judged the quality of the evidence for PHiD-CV10 to be moderate (further research is likely to have an
important impact on our confidence in the estimate of effect and may change the estimate). We judged the quality of the evidence for
PCV7 in older children with or without a history of respiratory illness to be high.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Pneumococcal conjugate vaccine versus control vaccine for preventing acute otitis media
Patient or population: infants (predominant ly < 6 months of age) and older children (aged 1 to 7 years)
Settings: community (Finland, the Netherlands, Czech Republic and Slovakia, Israel, USA, Argent ina, Colombia and Panama)
Intervention: mult ivalent PCVs
Comparison: control vaccine
PCV type VE - relative effect (95% CI)* No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Frequency of all- cause AOM (co-primary outcome)
CRM197-PCV7in low-risk infants RRR: 6% (−4% to 16%) to 6% (4%
to 9%)#
39,530 (2) ⊕⊕⊕⊕
high
Results are derived f rom 1 very large
trial including 37,868 infants, Black
2000/ Fireman 2003, and 1 smaller
trial including 1662 infants, Eskola
2001/ Palmu 2009, with low risk of
bias.
CRM197-PCV7in high-risk infants RRR:−5% (−25% to 12%) 944 (1) ⊕⊕⊕©
moderate1
Results are derived f rom 1 relat ively
small t rial with low risk of bias (
O’Brien 2008).
OMPC-PCV7 in low-risk infants RRR:−1% (−12% to 10%) 1666 (1) ⊕⊕⊕⊕
high
Results are derived f rom 1 trial with
low risk of bias (Kilpi 2003).
PHiD-CV10 in low-risk infants RRR: 6% (−6% to 17%) to 15%
(−1% to 28%)
12,454 (2) ⊕⊕⊕©
moderate2
Results are derived f rom 2 tri-
als with low, Tregnaghi 2014/ Sáez-
Llorens 2017, and unclear risk of bias
(Vesikari 2016).
AOM incidence rate in control group in
1 of the trials, Tregnaghi 2014/ Sáez-
Llorens 2017, was low compared to
the other studies (Table 1).
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PHiD-CV11 in low-risk infants RRR: 34% (21% to 44%) 4968 (1) ⊕⊕⊕⊕
high
Results are derived f rom 1 trial with
low risk of bias (Prymula 2006).
AOM incidence rate in control group
was low compared to other studies
(Table 1).
Adverse effects (co-primary outcome)
CRM197-PCV7in low-risk infants
OMPC-PCV7 in low-risk infants
PHiD-PC10/11 in low-risk infants
CRM197-PCV7/9 and CRM197-
PCV7 plus TIV in older children
Mild local react ions and fever
were common in both groups.
These adverse events occurred
more f requent ly in the PCV than
in the control vaccine groups: red-
ness (< 2.5 cm): 5% to 20%versus
0%to 16%, swelling (< 2.5 cm): 5%
to 12%versus 0% to 8%, and fever
(< 39 °C): 15% to 44% versus 8%
to 25%
More severe redness (> 2.5 cm)
, swelling (> 2.5 cm), and fever
(> 39 °C) occurred less f requent ly
(0% to 0.9%, 0.1% to 1.3%, and 0.
4% to 2.5%, respect ively in chil-
dren receiving PCV) and did not
dif f er signif icant ly between PCV
and control vaccine groups
Pain/ tenderness was reported
more f requent ly in children receiv-
ing PCV than in those receiving
control vaccines: 3% to 38% ver-
sus 0% to 8%
Serious adverse events judged
causally related to vaccinat ion
were rare and did not dif f er signif -
icant ly between vaccine groups.
No fatal serious adverse event
77,389 (9) ⊕⊕⊕⊕
high
Results are derived f rom 9 trials with
low risk of bias.
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judged causally related to vacci-
nat ion was reported
Frequency of pneumococcal AOM
CRM197-PCV7in low-risk infants RRR: 20% (7% to 31) to 34% (21%
to 45%)
1662 (1) ⊕⊕⊕⊕
high
Results are derived f rom 1 trial with
low risk of bias (Eskola 2001/ Palmu
2009).
OMPC-PCV7 in low-risk infants RRR: 25% (11% to 37%) 1666 (1) ⊕⊕⊕⊕
high
Results are derived f rom 1 trial with
low risk of bias (Kilpi 2003).
PHiD-CV10 in low-risk infants RRR: 53% (16% to 74%) 7359 (1) ⊕⊕⊕⊕
high
Results are derived f rom 1 trial with
low risk of bias (Tregnaghi 2014/
Sáez-Llorens 2017).
PHiD-CV11in low-risk infants RRR: 52% (37% to 63%) 4968 (1) ⊕⊕⊕⊕
high
Results are derived f rom 1 trial with
low risk of bias (Prymula 2006).
Frequency of recurrent AOM (defined as 3 or more AOM episodes in 6 months or 4 or more in 1 year)
CRM197-PCV7in low-risk infants RRR: 9% (−12% to 27%) to 10%
(7% to 13%)
39,530 (2) ⊕⊕⊕⊕
high
Results are derived f rom 1 very large
trial including 37,868 infants, Black
2000/ Fireman 2003, and 1 smaller
trial including 1662 infants, Eskola
2001/ Palmu 2009, with low risk of
bias.
PHiD-CV11in low-risk infants RRR: 56% (−2% to 80%) 4968 (1) ⊕⊕⊕©
moderate3
Results are derived f rom 1 trial with
low risk of bias (Prymula 2006).
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
* For readability purposes, absolute rates (episodes/ person-year and incidence rate dif ferences) are displayed in Table 1
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# Depending on whether the outcome was assessed by a composite of posit ive culture or posit ive pneumolysin polymerase chain react ion (PCR) or by posit ive culture only or
whether ITT or per-protocol analysis was performed
1We downgraded the quality of the evidence f rom high to moderate due to imprecise ef fect est imate (only one trial with
relat ively small sample size).
2We downgraded the quality of the evidence f rom high to moderate due to study lim itat ions (risk of bias) and imprecise ef fect
est imates.
3We downgraded the quality of the evidence f rom high to moderate due to the imprecise ef fect est imate.
AOM: acute ot it is media; CI: conf idence interval; CRM197-PCV7: 7-valent pneumococcal conjugate vaccine conjugated to
carrier protein CRM197; OMPC-PCV7: 7-valent pneumococcal conjugate vaccine conjugated to the outer membrane protein
complex of Neisseria meningitidis serogroup B; PCV: pneumococcal conjugate vaccine; PHiD-CV10: 10-valent pneumococcal
conjugate vaccine conjugated to protein D (surface lipoprotein of non-typeable Haemophilus influenzae); PHiD-CV11: 11-valent
pneumococcal conjugate vaccine conjugated to protein D (surface lipoprotein of non-typeable Haemophilus influenzae); RRR:
relat ive risk reduct ion; TIV: trivalent inf luenza vaccine; VE: vaccine ef f icacy
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B A C K G R O U N D
Description of the condition
Acute otitis media (AOM), defined as the presence of middle ear
fluid together with one or more signs or symptoms of acute mid-
dle ear inflammation such as otalgia, otorrhoea, fever, or irritabil-
ity, is one of the most common diseases in childhood and im-
poses a large burden on public health (Lieberthal 2013). Global
AOM incidence rates are highest in children one to four years
of age, with a peak incidence in six- to 11-month-old infants
(Monasta 2012). By the age of two years, up to 5% of all children
have experienced recurrent AOM, defined as three or more AOM
episodes in six months or four or more in one year (Kvaerner
1997; Lieberthal 2013). The three main bacterial pathogens iso-
lated from the middle ear fluid of children with AOM collected
before the widespread use of pneumococcal conjugate vaccines
(PCVs) were Streptococcus pneumoniae (25% to 39%), (non-ty-
peable) Haemophilus influenzae (12% to 23%), and Moraxella
catarrhalis (4% to 15%) (Bluestone 1992;Heikkinen 1999; Jacobs
1998; Luotonen 1981). Recent studies have shown that nation-
wide implementation of PCVs may have changed the frequency
of the causative otopathogens involved in AOM towards pneumo-
coccal serotypes not included in the vaccines and other bacteria in-
cluding non-typeable H influenzae (Allemann 2017; Barenkamp
2017; Casey 2013; Coker 2010; Kaur 2017; Somech 2011; Tamir
2015; Wiertsema 2011).
Description of the intervention
The marginal benefits of antibiotics for AOM in low-risk popula-
tions (Rovers 2006; Venekamp 2015); the increasing problem of
bacterial resistance against antibiotics (Laxminarayan 2013); and
the high estimated direct and indirect annual costs associated with
AOMhave prompted a search for effective vaccines to prevent this
condition (Ahmed 2014; Boonacker 2011). With S pneumoniae
(pneumococcus) being a common causative pathogen in child-
hood AOM and pneumonia, and one of the most frequent causes
of invasive bacterial disease such as bacteraemia and meningitis,
research has focused on the prevention of pneumococcal infections
by pneumococcal vaccines. Pneumococcal polysaccharide vaccines
(PPVs) have been available for decades, but have been shown to
be poorly immunogenic in children aged up to two years, who
are most prone to pneumococcal infections. In the most recent
versions of this review, no further attention has been paid to the
effect of PPVs, which were described in prior versions of this re-
view (Straetemans 2003).
The first pneumococcal conjugate vaccines (PCVs), in which the
pneumococcal capsular serotypes are covalently conjugated to car-
rier proteins, were developed in the 1990s and proved to be ade-
quately immunogenic in infants and toddlers (Dagan 1997; Eskola
1999; Shinefield 1999). Over the past decades, various PCVs have
been developed for use in children including:
• licenced 7-valent PCV containing the polysaccharides of
seven serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) conjugated
to the diphtheria-derived carrier protein CRM197 (CRM197-
PCV7);
• 7-valent PCV with the outer membrane complex of
Neisseria meningitidis serogroup B as carrier protein (OMPC-
PCV7);
• 9-valent PCV containing the capsular polysaccharides of
serotypes 1 and 5 in addition to those included in PCV7,
conjugated to CRM197 (CRM197-PCV9);
• licenced 10-valent PCV containing the capsular
polysaccharides of 10 serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C,
19F, and 23F) mostly conjugated to protein D, which is a surface
lipoprotein of H influenzae (PHiD-CV10);
• 11-valent containing the capsular polysaccharides of
serotype 3 as well as those included in PHiD-CV10 (PHiD-
CV11); and
• licenced 13-valent PCV containing the capsular
polysaccharides of 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14,
18C, 19A, 19F, and 23F) conjugated to CRM197 (CRM197-
PCV13).
How the intervention might work
Early and dense colonisation of the nasopharynx with bacterial
otopathogens, including S pneumoniae, increases the risk of AOM
substantially (Faden 1997; Leach 1994; Schilder 2016). As a con-
sequence, reducing or eliminating nasopharyngeal colonisation of
S pneumoniae by PCVsmay lead to reductions in AOM incidence.
In recent years, evidence has accumulated that PCVs might also
disrupt the continuum of evolution from pneumococcal-associ-
ated otitis media (OM) towards chronic/recurrent OMby preven-
tion of early vaccine-serotype AOM and thereby reducing subse-
quent and more complex disease caused by non-vaccine serotypes
and non-typeable H influenzae (Ben-Shimol 2014; Dagan 2016).
Why it is important to do this review
With AOM amongst the most common diseases in early child-
hood, the need for a vaccine to effectively prevent AOM is high.
Over the past decades various randomised controlled trials have
been performed to assess the effects of pneumococcal vaccination
to prevent AOM. From 2009 onwards, two multivalent PCVs
(PHiD-CV10 and CRM197-PCV13) have been licenced and
are being implemented in nationwide immunisation programmes
worldwide (WHO 2012). These new vaccines may have an in-
creased benefit in preventingAOM(Marom 2014;O’Brien2009).
As such, it was important to provide an up-to-date systematic re-
view on the effects of PCVs on preventing AOM.This review is an
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update of a Cochrane Review first published in 2002 (Straetemans
2002), and updated in 2004 (Straetemans 2004), 2009 (Jansen
2009), and 2014 (Fortanier 2014).
O B J E C T I V E S
To assess the effect of PCVs in preventing AOM in children up to
12 years of age.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), irrespective of type, assess-
ing the effect of pneumococcal conjugate vaccines (PCV) versus
placebo or control vaccine in preventing acute otitis media (AOM)
with a minimum follow-up duration of six months. As per previ-
ous versions of this review, we excluded studies that did not report
outcome data relevant for this review.
Types of participants
Children aged up to 12 years.
Types of interventions
PCV versus placebo or control vaccine.
Types of outcome measures
Primary outcomes
1. Frequency of all-cause AOM episodes defined as AOM
irrespective of causative pathogen. We considered this to be the
most relevant outcome for children, parents, and clinicians.
2. Adverse effects including local (redness, swelling) and
systemic reactions (fever), pain/tenderness, and serious adverse
events (SAEs) judged causally related to vaccination.
Secondary outcomes
1. Frequency of pneumococcal AOM.
2. Frequency of pneumococcal serotype-specific AOM
(including vaccine serotype, non-vaccine serotype, and cross-
reactive serotypes which are non-vaccine serotypes with a
serogroup that is included in the vaccine).
3. Frequency of recurrent AOM (defined as three or more
episodes in the last six months or four or more in the last year).
Search methods for identification of studies
The Cochrane Acute Respiratory Infections Group (2018 search
update) and Cochrane Infectious Disease Group (2019 search up-
date) Information Specialists conducted systematic searches for
RCTs and controlled clinical trials. There were no language, pub-
lication year, or publication status restrictions. The date of latest
search was 29 March 2019.
Electronic searches
For the 2014 review update, we used the search strategy presented
in Appendix 1.
For this 2019 update, we searched the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL; Issue 3, 2019), which
contains the Cochrane Acute Respiratory Infections Specialised
Register; MEDLINE (Ovid) (1995 to 29 March 2019); Embase
(Elsevier) (1995 to 29 March 2019); CINAHL (EBSCO) (Cu-
mulative Index to Nursing and Allied Health Literature) (2007
to 28 March 2019); LILACS (BIREME) (Latin American and
Caribbean Health Science Information database) (2007 to 28
March 2019), and Web of Science (Clarivate Analytics) (2007 to
28 March 2019).
We used the search strategy presented in Appendix 2 to search
CENTRALandMEDLINE.We combined theMEDLINEsearch
with the Cochrane Highly Sensitive Search Strategy for identify-
ing randomised trials in MEDLINE: sensitivity- and precision-
maximising version (2008 revision);Ovid format (Lefebvre 2011).
We adapted the search strategy to search Embase (Appendix 3),
CINAHL (Appendix 4), LILACS (Appendix 5), and Web of Sci-
ence (Appendix 6).
Searching other resources
To increase the yield of relevant studies, two review authors (ACF,
RPV) reviewed the reference lists of all relevant studies and review
articles retrieved.We searched theUSNational Institutes ofHealth
Ongoing Trials Register ClinicalTrials.gov ( clinicaltrials.gov/) (
Appendix 7) and the World Health Organization International
Clinical Trials Registry Platform (WHO ICTRP) ( www.who.int/
trialsearch) (Appendix 8) on 29 March 2019 for completed and
ongoing trials. We furthermore searched the internet (via Google
using the search terms ’pneumococcal conjugate vaccination for
acute otitis media trial’) and the extended abstracts published in
the Recent Advances inOtitisMedia (grey literature) on 29March
2019 for any additional trials.
Data collection and analysis
Selection of studies
Two review authors (ACF, RPV) independently screened titles and
abstracts obtained from the database searches and reviewed the
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full text of the potentially relevant titles and abstracts against the
inclusion criteria. Any disagreements were resolved by discussion.
Data extraction and management
Two review authors (ACF, RPV) independently extracted data
from the included studies. Any disagreements were resolved by
discussion.
Assessment of risk of bias in included studies
Two review authors (ACF, RPV) independently assessed the
methodological quality of the included trials. Any disagreements
were resolved by discussion. We assessed the methodological qual-
ity of included studies using the ’Risk of bias’ tool as described
in Chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011).We judged the following domains as
high, low, or unclear risk of bias: random sequence generation (se-
lection bias), concealment of allocation (selection bias), blinding
of participants and personnel (performance bias), blinding of out-
come assessment (detection bias), incomplete outcome data (at-
trition bias), selective reporting (reporting bias), and other sources
of bias.
Measures of treatment effect
We expressed estimates of treatment effects as relative risks/hazard
ratios with accompanying 95%confidence intervals (CIs). Vaccine
efficacy was estimated as 1 minus the relative risk/hazard ratio
(relative risk reduction (RRR)).
Unit of analysis issues
We included all types of RCTs. In the case of cluster-randomised
trials, we considered potential differences between the intervention
effects being estimated and checked whether clustering was taken
into account in the analysis of the individual trials.
Dealing with missing data
For each trial, we determined the number of missing data and
whether the authors took duration of follow-up (and censoring)
of individual participants into account in their statistical analyses.
Assessment of heterogeneity
We first assessed clinical heterogeneity across trials by reviewing
the differences in the types of participants recruited, interventions
used, and outcomes measured. We did not pool studies where
clinical heterogeneity made it unuseful to do so. Where studies
were sufficiently homogeneous, we proposed to assess statistical
heterogeneity for each outcome by visually inspecting the forest
plots and by using the Chi² test and the I² statistic.
Assessment of reporting biases
We proposed to assess reporting bias as within-study (outcome re-
porting) and between-study reporting (publication) bias (Higgins
2011).
Outcome reporting bias
We searched the internet, ClinicalTrials.gov, and the WHO IC-
TRP for available study protocols to determine whether outcomes
reported were predefined and whether all outcomes listed in the
study protocol were reported in the trial publications. Where in-
formation was insufficient to judge the risk of bias, we classified
the risk of bias as unclear (Higgins 2011).
Publication bias
We proposed a more formal method of assessing reporting bias,
that is by creating funnel plots, if sufficient trials (10 or more)
were available for an outcome.
Data synthesis
We primarily analysed the available data according to the inten-
tion-to-treat principle, that is by analysing all participants in the
groups to which they were originally randomised. As a secondary
analysis, we presented data based on a per-protocol analysis.
Where possible, we proposed conducting meta-analyses using Re-
view Manager 5 by calculating treatment effects with the Mantel-
Haenszel method, using a fixed-effect model where no substantial
statistical heterogeneity was present (I² < 50%) (Review Manager
2014). If substantial statistical heterogeneity was detected and un-
resolved by sensitivity analysis, we proposed to calculate treatment
effects using a random-effects (DerSimonian and Laird) model to
provide more conservative effect estimates. Where clinical hetero-
geneity precluded meta-analyses, we reported the effect estimates
as presented by the individual trials. If possible, we reported the
incidences of the various outcomes in the study arms together with
the vaccine efficacy estimates, with 95% CIs.
We proposed the following methods to conduct meta-analyses.
The generalised Cox proportional hazard method proposed by
Andersen 1982 is regarded as the most appropriate to assess the
effect of PCVs on AOM (Jahn-Eimermacher 2007). Under the as-
sumption that the hazard rate is proportional between both groups
over time, and that the risk of AOM is not affected by previous
episodes (although this is untrue), this model takes all available
information into account, that is all episodes (including recur-
rences), differences in individual patient follow-up time, and time
until a case of AOM (Jahn-Eimermacher 2007). However, infor-
mation on individual follow-up time until the first, second, third,
etc. case of AOM is difficult to obtain for each study to be in-
cluded in the meta-analysis. Poisson regression is based on the as-
sumption of a constant risk of AOM over time and that this risk is
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not affected by previous episodes of AOM. This method only re-
quires the total follow-up time and total number of episodes, and
therefore appears to be a more feasible method for meta-analysis.
Furthermore, Poisson regression seems not to be affected by the
deviation from a constant risk over time, having very similar results
for the effect of PCVs on AOM to the Andersen-Gill approach
(Jahn-Eimermacher 2007). For Poisson regression, the treatment
effect is measured as a rate ratio defined as follows: (total AOM
episodes in pneumococcal vaccination group divided by the num-
ber of children in the pneumococcal vaccination group multiplied
by the follow-up time in months) divided by (total AOM episodes
in control group divided by the number of children in the control
group multiplied by the follow-up time in months) (McCullagh
1989).
GRADE and ’Summary of findings’ table
We created Summary of findings for the main comparison for
PCVs administered in early infancy using the following outcomes:
frequency of all-cause AOM episodes (primary outcome), fre-
quency of pneumococcal AOM, and frequency of recurrent AOM
(defined as three or more AOM episodes in six months or four
or more in one year). We used the five GRADE considerations
(study limitations, consistency of effect, imprecision, indirectness,
and publication bias) to assess the quality of a body of evidence
as it relates to the studies that contribute data to the meta-anal-
yses for the prespecified outcomes (Atkins 2004). We judged the
quality of the evidence as high, moderate, low, or very low. We
judged evidence from RCTs that did not have serious limitations
as high quality. However, we downgraded the quality of evidence
to moderate, low, or very low based on the following factors: study
limitations (risk of bias), inconsistency (consistency of results),
imprecision (precision of results), indirectness of evidence (direct-
ness of evidence), and publication bias (existence of publication
bias). We used the methods and recommendations described in
Section 8.5 and Chapter 12 of the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011), employing GRADE-
pro GDT software (GRADEpro GDT 2015). We justified all de-
cisions to down- or upgrade the quality of studies using footnotes,
and made comments to aid the reader’s understanding of the re-
view where necessary.
Subgroup analysis and investigation of heterogeneity
Because the effect of PCVs on AOM may be influenced by the
age at which the PCV was administered, occurrence of previous
AOM or respiratory tract infection episodes, and by the type of
PCV used, we described the studies accordingly, that is we strati-
fied those with vaccination in early infancy versus those with vac-
cination later in childhood by type of PCV used.
Sensitivity analysis
We planned to carry out sensitivity analyses for risk of bias of in-
cluded studies to assess the robustness of review findings by ex-
cluding studies with high risk of bias (defined as high risk of allo-
cation concealment bias and attrition bias (overall loss to follow-
up of more than 20% or differential follow-up observed, or both))
from meta-analysis.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
This review is an update of a Cochrane Review first published
in 2002 (Straetemans 2002), and updated in 2004 (Straetemans
2004), 2009 (Jansen 2009), and 2014 (Fortanier 2014). In the
2014 review, which included studies up to December 2013, we
included nine RCTs, which were reported in 11 publications
(Black 2000/Fireman 2003; Dagan 2001; Eskola 2001/Palmu
2009; Jansen 2008; Kilpi 2003; O’Brien 2008; Prymula 2006; van
Kempen 2006; Veenhoven 2003).
For this update we searched electronic databases (December 2013
to March 2019) and retrieved 374 records. After removal of du-
plicates, we assessed 225 records by title and abstract, and iden-
tified eight potentially eligible studies which we obtained in full
text. After reviewing the full texts, we excluded two publications
that were additional analyses of the Eskola 2001 study but did not
include new outcome data useful to this review (Palmu 2015a;
Sarasoja 2013), and three publications that were secondary anal-
yses of the Finnish invasive pneumococcal disease (FinIP) vaccine
trial but did not report on any of our outcomes of interest (Palmu
2014; Palmu 2015b; Palmu 2018). This left three publications,
Sáez-Llorens 2017; Tregnaghi 2014; Vesikari 2016, that related to
two RCTs, Tregnaghi 2014; Vesikari 2016, that were suitable for
inclusion. Sáez-Llorens 2017 was a further analysis of Tregnaghi
2014. See Figure 1.
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Figure 1. Study flow diagram.
We did not identify additional relevant completed trials or any
ongoing studies by scanning the reference lists of relevant system-
atic reviews or by searching the internet, the grey literature, and
the trial registries ClinicalTrials.gov and WHO ICTRP.
Included studies
See Characteristics of included studies.
We included 11 RCTs reported in 14 publications (Black 2000/
Fireman 2003; Dagan 2001; Eskola 2001/Palmu 2009; Jansen
2008; Kilpi 2003; O’Brien 2008; Prymula 2006; Tregnaghi 2014/
Sáez-Llorens 2017; van Kempen 2006; Veenhoven 2003; Vesikari
2016). We added two RCTs (reported in three publications) for
this update (Tregnaghi 2014/Sáez-Llorens 2017; Vesikari 2016).
The included trials involved a total of 60,733 children.
Study designs
Of the 11 included studies, nine were standard, individually ran-
domised trials, and twowere cluster-RCTs (O’Brien 2008;Vesikari
2016). Both cluster-RCTs took the cluster effect into account in
their analyses.
Study populations (early infancy versus later in life)
In seven trials (Black 2000/Fireman 2003; Eskola 2001/Palmu
2009; Kilpi 2003; O’Brien 2008; Prymula 2006; Tregnaghi 2014/
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Sáez-Llorens 2017; Vesikari 2016), PCVs were predominantly ad-
ministered in children’s first six months of life. Four trials, Dagan
2001; Jansen 2008; van Kempen 2006; Veenhoven 2003, assessed
the effects of PCVs administered at a later age on AOM in ei-
ther healthy infants, Dagan 2001, or in children with a history of
respiratory illness or frequent AOM (Jansen 2008; van Kempen
2006; Veenhoven 2003). Three trials were performed in Finland
(Eskola 2001/Palmu 2009; Kilpi 2003; Vesikari 2016), two in
the USA (Black 2000/Fireman 2003; O’Brien 2008), two in the
Netherlands (Jansen 2008; Veenhoven 2003), and the remaining
in Belgium (van Kempen 2006), Israel (Dagan 2001), Czech Re-
public and Slovakia (Prymula 2006), and Argentina, Colombia,
and Panama (Tregnaghi 2014/Sáez-Llorens 2017). Most of these
countries had AOM diagnosis and management guidelines at the
time of the study (Tamir 2017).
Interventions
Type of PCV used and co-administration of other vaccines
In six trials, CRM197-PCV7 was used as the intervention (Black
2000/Fireman 2003; Eskola 2001/Palmu 2009; Jansen 2008;
O’Brien 2008; van Kempen 2006; Veenhoven 2003). In two
studies, a booster dose with 23-valent PPV (containing capsular
polysaccharides of the serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V,
10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and
33F) was given to all children (van Kempen 2006; Veenhoven
2003). In one trial, CRM197-PCV7 was administered together
with a trivalent inactivated influenza vaccine (TIV) (Jansen 2008).
Four different interventions were used in five trials: OMPC-PCV7
in Kilpi 2003 (a subset of these children received PPV23 as a
booster dose); CRM197-PCV9 in Dagan 2001; PHiD-CV10 in
Tregnaghi 2014/Sáez-Llorens 2017 andVesikari 2016; and PHiD-
CV11 in Prymula 2006.
Comparator
Control vaccines were used as comparators in all trials. Com-
parator vaccines included meningococcus type C conjugate vac-
cine (10 µg of group C oligosaccharide conjugated to carrier pro-
tein CRM197; MenC) in three trials (Black 2000/Fireman 2003;
Dagan 2001; O’Brien 2008), whilst hepatitis A or B vaccine was
used in the remaining eight trials.
Outcome measures
Adverse effects were reported in nine trials including a total of
77,389 children (Black 2000/Fireman 2003; Dagan 2001; Eskola
2001/Palmu 2009; Jansen 2008; Kilpi 2003; Prymula 2006;
Tregnaghi 2014/Sáez-Llorens 2017; Veenhoven 2003; Vesikari
2016). Tregnaghi 2014/Sáez-Llorens 2017 was part of the Clinical
Otitis Media and Pneumonia Study (COMPAS; clinicaltrials.gov/
show/NCT00466947), which assessed the efficacy and safety of
PHiD-CV10 against invasive pneumococcal disease, community-
acquired pneumonia, and AOM in 23,821 young Latin Ameri-
can children. Acute otitis media was studied in the Panama co-
hort only, which included 7357 children, whereas safety data were
available for all 23,821 children.
Six trials applied a standardised diagnosis of AOM (Eskola 2001/
Palmu 2009; Kilpi 2003; Prymula 2006; Tregnaghi 2014/Sáez-
Llorens 2017; van Kempen 2006; Veenhoven 2003), and one trial
used standardised AOM registration forms to be completed by
general practitioners (Jansen 2008). In two trials, AOM episodes
were extracted from a computerised data source containing all vis-
its registered by physicians (Black 2000/Fireman 2003; O’Brien
2008). Two trials relied on parent-reportedAOMepisodes (Dagan
2001; Vesikari 2016); Vesikari 2016 used parent-reported, physi-
cian-confirmed AOM as the outcome of interest. Two trials
assessed outcomes during influenza seasons (Jansen 2008; van
Kempen 2006).
Seven trials also assessed the effect of PCVs on (serotype-specific)
pneumococcal AOM (Black 2000/Fireman 2003; Eskola 2001;
Kilpi 2003; O’Brien 2008; Prymula 2006; Tregnaghi 2014/Sáez-
Llorens 2017;Veenhoven 2003). Three studies culturedmiddle ear
fluid from all AOM episodes (Eskola 2001; Kilpi 2003; Prymula
2006), and one trial cultured middle ear fluid by tympanocentesis
when fluid was suspected in the middle ear (Tregnaghi 2014/Sáez-
Llorens 2017). One trial only cultured middle ear fluid from the
first AOM episode by tympanocentesis or from spontaneously
draining ears (Veenhoven 2003). Two trials assessed the effect on
reported cultures that were obtained from spontaneously draining
ears (Black 2000/Fireman 2003; O’Brien 2008).
Three trials reported the effects of PCVs on recurrent AOM(Black
2000/Fireman 2003; Eskola 2001; Prymula 2006). Three studies
included all types of OM, including but not exclusively AOM,
as an outcome (Black 2000/Fireman 2003; Dagan 2001; O’Brien
2008).
Funding and conflicts of interest
Six trials were funded by pharmaceutical companies (Black 2000/
Fireman; Eskola 2001/Palmu 2009; Kilpi 2003; Prymula 2006;
Tregnaghi 2014/Sáez-Llorens 2017; Vesikari 2016). Three trials
reported receiving support from non-commercial (governmental)
sources, but study vaccines were supplied by pharmaceutical com-
panies (Jansen 2008; van Kempen 2006; Veenhoven 2003). One
trial was supported both by a pharmaceutical company and govern-
mental funding (O’Brien 2008).One trial reported that study vac-
cines were supplied by a pharmaceutical company (Dagan 2001).
Brief overview of clinical heterogeneity across included
studies
There was considerable clinical heterogeneity across the included
trials. There were differences in the timing of PCV administration,
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that is trials administering PCV during infancy and trials admin-
istering PCV later in life. As such, study populations varied from
healthy infants to those at high risk of AOM. Secondly, the num-
ber of pneumococcal serotypes present in the vaccines, the type of
conjugate method used, and co-administration of other vaccines
differed substantially across trials. Study designs also varied, in-
cluding both individually randomised controlled trials and cluster-
RCTs. Finally, large differences in outcome assessments and AOM
definitions were observed, varying from ’passive’ (chart review at
the end of the trial) to ’active’ (parents were instructed to visit a
physician in case of AOM symptoms) outcome assessments and
physician-confirmed AOM episodes versus parent-reported AOM
episodes.Consequently, AOMincidence in the control groups var-
ied widely across the studies administering PCV during infancy,
that is from 0.13 to 1.3 episodes per person-year.We therefore did
not perform meta-analyses.
Excluded studies
In the 2014 version of this review (Fortanier 2014), four studies
were excluded since they (i) did not include a control vaccine
(Gisselsson-Solen 2011); (ii) did not report outcome data relevant
for this review (Jokinen 2012); (iii) assessed the effect of PCV
on otitis media with effusion rather than AOM (Le 2007); and
(iv) reported the effect of PCV on suppurative otitis media in
an abstract of a conference meeting (Roy 2011). In this 2019
update, a further five studies were excluded that did not report
outcome data relevant for this review (Palmu 2014; Palmu 2015a;
Palmu 2015b; Palmu 2018; Sarasoja 2013). See Characteristics of
excluded studies.
Ongoing studies
We did not identify any ongoing studies.
Risk of bias in included studies
We judged the methodological quality of the included studies to
be moderate to high. We presented the ’Risk of bias’ assessment
graphically in Figure 2 and Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Eight included trials described concealment of allocation ade-
quately, whilst this domain was assessed as unclear for three trials
due to insufficient information (Black 2000/Fireman 2003; Jansen
2008; Veenhoven 2003). We judged random sequence generation
to be adequate in seven trials, whilst four trials provided insuf-
ficient information on methods of random sequence generation
used (Black 2000/Fireman 2003; Dagan 2001; Jansen 2008; van
Kempen 2006).
Blinding
Although all studies indicated that trials were double-blinded,
three trials provided insufficient information about how blind-
ing was performed (Black 2000/Fireman 2003; Prymula 2006;
Vesikari 2016).
Incomplete outcome data
We judged risk of attrition bias to be high in one trial (Vesikari
2016), unclear in three trials (Black 2000/Fireman 2003; Jansen
2008; O’Brien 2008), and low in seven trials.
Selective reporting
We judged risk of reporting bias to be unclear in six trials, Black
2000/Fireman 2003; Dagan 2001; Eskola 2001/Palmu 2009;
Kilpi 2003; van Kempen 2006; Veenhoven 2003, and low in five
trials.
Other potential sources of bias
We judged risk of bias due to other sources (including balances in
baseline characteristics, use of co-intervention across groups, pres-
ence of formal sample size calculations, and (prespecified) interim
analyses) as unclear in three trials, Black 2000/Fireman 2003; Kilpi
2003; O’Brien 2008, and low in the remaining eight trials.
Effects of interventions
See: Summary of findings for the main comparison
Pneumococcal conjugate vaccine versus control vaccine for
preventing acute otitis media
Effect estimates of the various PCV types, stratified by the age at
which PCVs were administered and the occurrence of previous
AOM/respiratory tract infection (RTI) episodes (i.e. administra-
tion in early infancy versus later in life), on frequency of all-cause
AOM, (vaccine-type) frequency of pneumococcal AOM, and fre-
quency of recurrentAOM(defined as three ormoreAOMepisodes
in six months or four or more in one year), are summarised in
Table 1, Table 2, and Table 3, respectively. The main results for
PCVs administered in early infancy are described in Summary of
findings for the main comparison.
We included a total of 14 publications of 11 RCTs (60,733 chil-
dren, range 74 to 37,868 per trial) of 7- to 11-valent PCVs ver-
sus control vaccines. Seven trials included infants who predom-
inantly received primary vaccinations before six months of age
(59,415 children in total) (Black 2000/Fireman 2003; Eskola
2001/Palmu 2009; Kilpi 2003; O’Brien 2008; Prymula 2006;
Tregnaghi 2014/Sáez-Llorens 2017; Vesikari 2016). One study in-
cluded day-care attendees aged from 12 to 35 months (264 chil-
dren) (Dagan 2001). Two trials included children aged from one
to seven years with a history of AOM (457 children) (van Kempen
2006; Veenhoven 2003). One trial included children aged from
18 to 72 months with a previously diagnosed RTI (597 children)
(Jansen 2008).
We have presented the results of individual trials as reported in
the published papers; meta-analysis was inappropriate due to sub-
stantial differences among studies. We have assessed the statistical
methods used to analyse data in each study.
Adverse effects (co-primary outcome)
An overview of adverse effects reported in the individual studies
can be found in Table 4.
Mild local reactions and fever were common in both groups, oc-
curring more frequently in the PCV than in the control vaccine
groups: redness (< 2.5 cm): 5% to 20%versus 0% to 16%; swelling
(< 2.5 cm): 5% to 12% versus 0% to 8%; and fever (< 39 °C):
15% to 44% versus 8% to 25%. More severe redness (> 2.5 cm),
swelling (> 2.5 cm), and fever (> 39° C) occurred less frequently
(0% to 0.9%, 0.1% to 1.3%, and 0.4% to 2.5%, respectively, in
children receiving PCV) and did not differ significantly between
PCV and control vaccine groups. Pain or tenderness, or both was
reported more frequently in children receiving PCV than in those
receiving control vaccines: 3% to 38% versus 0% to 8%. Serious
adverse events (SAEs) judged causally related to vaccination were
rare and did not differ significantly between vaccine groups. No
fatal SAE judged causally related to vaccination was reported.
The evidence for this outcome was of high quality.
Acute otitis media outcomes (co-primary outcome
and secondary outcomes)
Seven studies used the generalised Cox proportional hazard
method proposed by Andersen 1982, currently regarded as the
most optimal for analysing this kind of data (Black 2000/
Fireman 2003; Eskola 2001/Palmu 2009; Kilpi 2003; Prymula
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2006; Tregnaghi 2014/Sáez-Llorens 2017; van Kempen 2006;
Veenhoven 2003).
Dagan 2001 compared rates of AOM, but rather than comparing
them by Poisson or negative binomial regression analysis (which
would presumably yield results similar to those obtained with the
Andersen approach), the Chi² test was used, which is suboptimal
for comparing rates.
Jansen 2008 used Poisson, and Vesikari 2016 used negative bino-
mial regression analysis to compare rates of AOMbetween groups,
accounting for the potential dependency of observations between
individuals.
O’Brien 2008 was a cluster-randomised trial that calculated inci-
dence rate ratios with a Poisson regression with sandwich variance
estimation to account for within-community correlation.
Effect of PCV administered in early infancy (predominantly
< 6 months of age)
Seven trials (59,415 children) included infants who predomi-
nantly received various types of PCV before six months of age
(Black 2000/Fireman2003; Eskola 2001/Palmu2009;Kilpi 2003;
O’Brien2008; Prymula2006;Tregnaghi 2014/Sáez-Llorens 2017;
Vesikari 2016)
PCV7
In two trials (39,530 children), CRM197-PCV7 was the inter-
vention for healthy infants aged two months (Black 2000/Fire-
man 2003; Eskola 2001/Palmu 2009). The same vaccine was used
as the intervention in one trial including 944 Navajo and White
Mountain Apache children aged up to two years. These children
carry one of the highest risks of developing AOM in the world
(O’Brien 2008).
In one trial (1666 children), OMPC-PCV7, with a subset of chil-
dren receiving PPV23 as a booster dose, was used as the interven-
tion in healthy infants aged two months (Kilpi 2003).
Primary outcome
• Frequency of all-cause AOM episodes
In one trial including 37,868 healthy infants aged two months
(Black 2000/Fireman 2003), CRM197-PCV7 was associated with
a 6% (95% confidence interval (CI) 4% to 9%) relative risk re-
duction (RRR) in all-cause AOM episodes in an intention-to-
treat (ITT) analysis. Per-protocol analysis of a trial including 1662
healthy infants aged two months showed that this same vaccine
was associated with a non-significant 6% (95% CI −4% to 16%)
RRR in all-cause AOM episodes (Eskola 2001/Palmu 2009).
In young children who carry a high baseline risk of developing
AOM, CRM197-PCV7 was not associated with a reduction in
all-cause AOM episodes (1 trial; 944 children; RRR −5%, 95%
CI −25% to 12%; ITT analysis) (O’Brien 2008).
In one trial including 1666 healthy infants aged twomonths (Kilpi
2003), OMPC-PCV7 was not associated with a reduction in all-
cause AOM episodes in per-protocol analysis (RRR −1%, 95%
CI −12% to 10%).
The evidence for the use of CRM197-PCV7 and OMPC-PCV7
in low-risk infants for this outcome was of high quality. However,
the evidence for use of CRM197-PCV7 in young children with
high baseline risk of developing AOM for this outcome was of
moderate quality; the evidence quality was downgraded one level
due to imprecise effect estimate (one trial with a relatively small
sample size).
Secondary outcomes
• Frequency of pneumococcal AOM
In one trial including 1662 healthy infants aged two months (
Eskola 2001/Palmu 2009), CRM197-PCV7 was associated with a
20% (95%CI 7% to 31%) to 34% (95%CI 21% to 45%)RRR in
pneumococcal AOM episodes in per-protocol analysis, depending
on whether this outcome was assessed by a composite of positive
culture or positive pneumolysin polymerase chain reaction (PCR)
or by positive culture only.
In one trial including 1666 healthy infants aged twomonths (Kilpi
2003), OMPC-PCV7 was associated with a 25% (95% CI 11%
to 37%) RRR in pneumococcal AOM episodes in per-protocol
analysis.
The evidence for this outcome was of high quality.
• Frequency of pneumococcal serotype-specific AOM
In two trials (39,530 healthy infants aged two months) (Black
2000/Fireman 2003; Eskola 2001/Palmu 2009), administration
of CRM197-PCV7 was associated with a 54% (95% CI 41%
to 64%) to 65% (P = 0.04) RRR in vaccine-type pneumococcal
AOM episodes in ITT analysis.
In one of these trials (Eskola 2001/Palmu 2009), CRM197-PCV7
was associated with a 51% (95% CI 27% to 67%) RRR in AOM
episodes caused by cross-reactive serotypes and a non-significant
33% (95% CI −80% to 1%) relative increase in the risk of non-
vaccine type AOM episodes in per-protocol analyses.
In one trial (944 children) (O’Brien 2008), administration of
CRM197-PCV7 in young children who carry a high baseline risk
of developing AOM was associated with a non-significant 64%
(95% CI −34% to 90%) RRR in vaccine-type pneumococcal
AOM episodes in ITT analysis.
In one trial including 1666 healthy infants aged twomonths (Kilpi
2003), OMPC-PCV7was associated with a 56% (95%CI 44% to
66%) RRR in vaccine-type pneumococcal AOM episodes in per-
protocol analysis. In the same trial (Kilpi 2003), OMPC-PCV7
failed to show cross-protection (RRR −5%, 95% CI −47% to
25%), and this vaccine was associated with a non-significant 27%
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(95%CI−70% to 6%) relative increase in the risk of non-vaccine-
type AOM episodes in per-protocol analyses.
The evidence for use of CRM197-PCV7 and OMPC-PCV7 in
healthy infants for this outcome was of high quality. However,
evidence for the use of CRM197-PCV7 in young children with
high baseline risk of developing AOM for this outcome was of
moderate quality; the evidence quality was downgraded one level
due to study limitations (risk of bias) and imprecise effect estimate.
• Frequency of recurrent AOM
In two trials (39,530 children) (Black 2000/Fireman 2003; Eskola
2001/Palmu 2009), administration of CRM197-PCV7 in healthy
infants aged twomonthswas associatedwith a 9% (95%CI−12%
to 27%) to 10% (95% CI 7% to 13%) RRR in developing recur-
rent AOM.
The evidence for this outcome was of high quality.
PHiD-CV10/11
PHiD-CV10 was used as the intervention in two trials (12,307
children) (Tregnaghi 2014/Sáez-Llorens 2017; Vesikari 2016).
PHiD-CV11 was used in one trial (4968 children) (Prymula
2006).
Primary outcome
• Frequency of all-cause AOM episodes
In one trial including 7359 healthy infants aged from 6 to 16
weeks (Tregnaghi 2014/Sáez-Llorens 2017), PHiD-CV10 was as-
sociated with a non-significant 15% (95%CI−1% to 28%) RRR
in all-cause AOM episodes in ITT analysis. Per-protocol analysis
of a trial including 5095 healthy infants aged from 6 weeks to 18
months showed that this same vaccine was associated with a non-
significant 6% (95% CI −6% to 17%) RRR in all-cause AOM
episodes (Vesikari 2016).
In one trial including 4968 healthy infants aged from 6 weeks to
5 months, PHiD-CV11 was associated with a 34% (95% CI 21%
to 44%) RRR in all-cause AOM episodes in per-protocol analysis
(Prymula 2006).
However, it should be noted that the AOM incidence rates in the
two trials with the largest point estimates, Tregnaghi 2014/Sáez-
Llorens 2017; Prymula 2006, were low (Table 1). Consequently,
the absolute risk differences in these trials were rather small.
The evidence for the use of PHiD-CV11 for this outcome was
of high quality. The evidence for the use of PHiD-CV10 was
of moderate quality; the evidence quality was downgraded one
level due to study limitations (risk of bias) and imprecise effect
estimates.
Secondary outcomes
• Frequency of pneumococcal AOM
In one trial including 7359 healthy infants aged from6 to 16weeks
(Tregnaghi 2014/Sáez-Llorens 2017), PHiD-CV10 was associated
with a 53% (95% CI 16% to 74%) RRR in pneumococcal AOM
episodes in ITT analysis.
In one trial including 4968 healthy infants aged from 6 weeks to
5 months, PHiD-CV11 was associated with a 52% (95% CI 37%
to 63%) RRR in pneumococcal AOM episodes in per-protocol
analysis (Prymula 2006).
The evidence for pneumococcal AOM episodes was of high qual-
ity.
• Frequency of pneumococcal serotype-specific AOM
In one trial including 7359 healthy infants aged from 6 to 16
weeks (Tregnaghi 2014/Sáez-Llorens 2017), PHiD-CV10 was as-
sociated with a 70% (95% CI 30% to 87%) RRR in vaccine-type
pneumococcal AOM episodes in ITT analysis. In the same trial
(Tregnaghi 2014/Sáez-Llorens 2017), PHiD-CV10 was associated
with a non-significant 29% (95% CI −123% to 77%) RRR in
AOM episodes caused by cross-reactive serotypes and a non-sig-
nificant 15% (95%CI−153% to 71%) RRR in non-vaccine-type
AOM episodes in ITT analyses.
In one trial including 4968 healthy infants aged from 6 weeks to
5 months, PHiD-CV11 was associated with a 58% (95% CI 41%
to 69%) RRR in vaccine-type pneumococcal AOM episodes in
per-protocol analysis (Prymula 2006). In the same trial (Prymula
2006), PHiD-CV11 was associated with a 66% (95% CI 22% to
85%) RRR in AOM episodes caused by cross-reactive serotypes
and a non-significant 9% (95% CI −64% to 49%) RRR in non-
vaccine-type AOM episodes in per-protocol analyses.
The evidence for vaccine-type pneumococcal AOM episodes was
of high quality. The evidence for cross-reactive serotypes and non-
vaccine-type AOM episodes was of moderate quality; the evidence
quality was downgraded one level due to imprecise effect estimates.
• Frequency of recurrent AOM
In one trial including 4968 healthy infants aged from 6 weeks to 5
months, PHiD-CV11 was associated with a non-significant 56%
(95% CI −2% to 80%) RRR in developing recurrent AOM in
per-protocol analysis (Prymula 2006).
The evidence for this outcome was of moderate quality; the evi-
dence quality was downgraded one level due to the imprecise effect
estimate.
Effect of PCV administered at a later age (one year and
above)
In three trials, various types of PCV7were administered in children
with a history of either RTI (597 participants), Jansen 2008, or
AOM (457 participants in total) (van Kempen 2006; Veenhoven
2003).
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CRM197-PCV7
Primary outcome
• Frequency of all-cause AOM episodes
In two trials (457 children) (van Kempen2006; Veenhoven 2003),
CRM197-PCV7 followed by PPV23 in children aged from one to
seven years with a history of AOMwas not associated with further
reductions in AOM episodes (1 trial; 383 children; RRR −25%,
95% CI −57% to 1%; ITT-analysis (Veenhoven 2003); 1 trial;
74 children; RRR −16%, 95% CI −96% to 31%; per-protocol
analysis (van Kempen 2006)).
In one trial including 597 children with a history of RTI (Jansen
2008), CRM197-PCV7 administered together with a trivalent
influenza vaccine (CRM197-PCV7/TIV) was associated a 57%
(95% CI 6% to 80%) RRR in all-cause AOM episodes compared
to hepatitis B/placebo vaccination in per-protocol analysis. How-
ever, the effect of TIV/placebo compared to hepatitis B/placebo
vaccination on all-cause AOM episodes appeared to be even larger
(RRR 71%, 95% CI 30% to 88%) (Jansen 2008).
The evidence for this outcome was of high quality.
Secondary outcomes
• Frequency of pneumococcal AOM
In per-protocol analysis of one trial including 383 children with
a history of AOM (Veenhoven 2003), CRM197-PCV7 followed
by PPV23 was associated with a non-significant 34% (P = 0.22)
RRR in pneumococcal AOM episodes.
The evidence for this outcome was of moderate quality; the ev-
idence quality was downgraded one level due to imprecise effect
estimates (one study with a relatively small sample size).
• Frequency of pneumococcal serotype-specific AOM
In a per-protocol analysis of one trial including 383 childrenwith a
history of AOM (Veenhoven 2003), CRM197-PCV7 followed by
PPV23 was associated with a non-significant 52% (P = 0.21) and
21% (P = 0.21) RRR in pneumococcal serotype-specific AOM
and non-vaccine-type AOM episodes.
The evidence for this outcome was of moderate quality; the ev-
idence quality was downgraded one level due to imprecise effect
estimates (one study with a relatively small sample size).
• Frequency of recurrent AOM
None of the three trials in older children reported the effect of
PCV7 on recurrent AOM.
CRM197-PCV9
In one trial (264 children) (Dagan 2001), CRM197-PCV9 was
administered in healthy day-care attendees aged from 12 to 35
months.
Primary outcome
• Frequency of all-cause AOM episodes
In a per-protocol analysis, CRM197-PCV9 was associated with
a non-significant 17% (95% CI −2% to 33%) RRR in all-cause
OM episodes (Dagan 2001).
The evidence for this outcome was of low quality; the evidence
quality was downgraded two levels due to study limitations (risk
of bias and questions about outcome assessment) and imprecise
effect estimate (one study with a relatively small sample size).
Secondary outcomes
Dagan 2001 did not report on any of our secondary outcomes of
interest.
D I S C U S S I O N
Summary of main results
The current evidence base for the effects of PCVs for preventing
AOM in children comes from 11 RCTs (60,733 children) of 7-
to 11-valent PCVs versus control vaccines (meningococcus type
C conjugate vaccine in three trials, and hepatitis A or B vaccine in
eight trials) with a generally low risk of bias. No relevant RCTswith
the newer 13-valent PCV were available. In seven trials (59,415
children), PCVs were predominantly administered in children’s
first months of life, whilst four trials (1318 children) included
children aged one year and over who were either healthy or who
had a history of respiratory illness or frequent AOM. There was
considerable clinical heterogeneity across studies in terms of de-
sign, study population, type of PCV used, and outcome measures,
therefore we did not perform meta-analyses.
The licenced CRM197-PCV7 and PHiD-CV10 vaccines, when
administered during early infancy (< 6 months of age), were asso-
ciated with substantial RRR in pneumococcal AOM (high-qual-
ity evidence). However, their effects on all-cause AOM are far
more uncertain, as most trials failed to demonstrate statistical
significant differences for this outcome. Relative risk reductions
for CRM197-PCV7 varied from −5% (95% CI −25% to 12%)
in high-risk infants (moderate-quality evidence) to 6% (95% CI
−4% to 16%) and 6% (95% CI 4% to 9%) in low-risk infants
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(high-quality evidence); whereas RRRs for PHiD-CV10 varied
from 6% (95% CI−6% to 17%) to 15% (95% CI−1% to 28%)
in healthy infants (moderate-quality evidence).
Administration of PCVs in high-risk infants, after early infancy,
and in older children with a history of a history of respiratory
illness or frequent AOMwas not associated with reductions in all-
cause AOM.
Local redness, swelling, fever, and tenderness/painwere commonly
reported and occurred more frequently in children receiving PCV
than in those receiving control vaccines, but these adverse effects
were mostly mild. More severe redness (> 2.5 cm), swelling (>
2.5 cm), and fever (> 39 °C) occurred far less frequently and did
not differ between vaccine groups. Serious adverse events judged
causally related to vaccination were rare and did not differ sig-
nificantly between vaccine groups. No fatal SAE judged causally
related to vaccination was reported.
Overall completeness and applicability of
evidence
The 11 RCTs included in this review differed substantially in
terms of RCT type, study population (age of PCV administration
and AOM baseline risk), PCV type (vaccine valency, carrier pro-
tein, and booster regimen), co-administration of other vaccines,
and AOM assessment and definition used. Furthermore, in the
infant studies focusing on AOM bacteriology (Eskola 2001; Kilpi
2003; Prymula 2006; Tregnaghi 2014), the control groups varied
markedly in the proportions of S pneumoniae, H influenzae, and
M catarrhalis found in the middle ear fluid. This might be related
to time and geographic region as well as case definition, and has
important implications for the effects of PCV on preventing all-
cause AOM episodes. Additionally, three studies included older
otitis-prone children, so the intervention was aimed at secondary
or even tertiary prevention, and not primary prevention (Jansen
2008; van Kempen 2006; Veenhoven 2003). The reduced efficacy
of CRM197-PCV7 in children with a history of AOM may be
explained by an increased susceptibility to subsequent infections,
not only with non-vaccine-type pneumococci, but also other na-
sopharyngeal colonisers, due to ’damage’ already suffered by the
middle ear mucosa caused by prior AOM (Veenhoven 2003). An-
other explanation, although debated, could be the non-protec-
tive, impaired antibody responses of children who are otitis-prone
(Pichichero 2013; Wiertsema 2012). It thus appears that the age
at which PCV is administered, a history of AOM episodes, or
both, modifies the effect of PCV on AOM, despite the fact that
age alone could not be identified as a statistically significant effect
modifier (Black 2000/Fireman 2003; Veenhoven 2003). Our re-
view did not focus on the effects of PCVs on shifts in serotypes
over time. Further research into the impact of PCVs on (serotype)
replacement is warranted since a shift in causative pathogens may
have considerable implications on both AOM burden and vaccine
effectiveness.
Quality of the evidence
We judged the methodological quality of the included studies to
be generally high. For most outcomes, the quality of the evidence
varied from high (further research is very unlikely to change our
confidence in the estimate of effect) to moderate (further research
is likely to have an important impact on our confidence in the
estimate of effect and may change the estimate). The evidence
for the effect of CRM197-PCV9 administered in healthy day-care
attendees aged 12 to 35 months on all-cause AOM episodes was
of low quality (further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to
change the estimate).
Potential biases in the review process
We adhered to the prespecified review protocol. In this 2019 up-
date, two review authors (ACF and RPV) independently searched
all relevant electronic databases using a search syntax comprising
all relevant synonyms for PCV and AOM. We also performed a
broad internet search to identify potentially relevant articles. To
increase the yield of relevant studies, we reviewed the reference
lists of all identified studies and systematic reviews or meta-anal-
yses. We searched ClinicalTrials.gov and the WHO ICTRP for
completed and ongoing trials.
Agreements and disagreements with other
studies or reviews
Our main findings are in agreement with two other systematic
reviews on the effect of PCV in children, indicating that PCVs
provide substantial protection against pneumococcal AOM, but
that their effects on all-cause AOM are more uncertain and far less
pronounced (Ewald 2016; Pavia 2009; Taylor 2012).
In AOM, there is a high potential for replacement by other bac-
terial pathogens that are common colonisers of the nasopharynx.
CRM197-PCV7 is known to affect nasopharyngeal carriage of
pneumococci, with a shift from vaccine-type pneumococci to non-
vaccine-type pneumococci andother otopathogens includingnon-
typeable H influenza and Staphylococcus aureus (Biesbroek 2014;
Block 2006; Casey 2013; Coker 2010; Eskola 2001; Obaro 1996;
Somech 2011; van Gils 2011; Wiertsema 2011). Nasopharyngeal
carriage results from a recent RCT on PHiD-CV10 showed simi-
lar bacterial colonisation patterns as observed in CRM197-PCV7
among healthy Dutch children aged up to two years (van den
Bergh 2013). Themiddle ear is directly connected to the nasophar-
ynx, and by lowering the carriage of vaccine-type pneumococci, a
niche may be created for other bacteria with pathogenic potential
(Block 2006; Veenhoven 2003; Veenhoven 2004). Recent studies
have shown that nationwide implementation of PCVs may have
changed the frequency of the causative otopathogens involved in
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AOM towards pneumococcal serotypes not included in the vac-
cines and non-typeable H influenzae (Casey 2013; Coker 2010;
Kaur 2017; Somech 2011; Wiertsema 2011).
Although RCT data failed to demonstrate a convincing bene-
ficial effect of CRM197-PCV7 and PHiD-CV10 on all-cause
AOM, various global postmarketing studies with these licenced
vaccines, as well as the newer CRM197-PCV13, suggest that the
impact of PCVs on AOM may be substantial (Eythorsson 2018;
Gisselsson-Solen 2017; Kawai 2018; Lau 2015; Magnus 2012;
Marom 2014; Poehling 2007; Sigurðsson 2018; Zhou 2008),
which may be attributable to indirect (herd) effects of vaccination.
However, it should be noted that findings fromobservational stud-
ies warrant careful interpretation, as variability in baseline inci-
dence, study population, and case definition, as well as fluctuations
in risk factors for AOM such as breastfeeding, household smoking,
day-care attendance rates, and implementation of AOM clinical
practice guidelines, may affect the AOM incidences reported. For
example, results from Boston (USA) showed that the decline in
uncomplicated AOM, treatment failure, and AOM relapse was at
least as large in the 2000 to 2004 period compared to the 1996 to
2000 period, leaving the ’true’ contribution of PCV in reducing
AOM incidence uncertain (Sox 2008). Furthermore, reduced ex-
posure to household smoking, among other factors such as PCV7
coverage since 2002, may have contributed to the steady decline
in USA paediatric ambulatory visits for OM over the period of
1993 to 2006 (Alpert 2011).
The impact of PHiD-CVs may expand beyond their effects on
pneumococcal AOM to AOM caused by non-typeableH influen-
zae due to the carrier protein D (Forsgren 2008). A recent re-
view including pre-clinical, clinical, and postmarketing studies
concluded that PHiD-CVs may decrease AOM caused by non-
typeableH influenzae, but that more evidence including pathogen-
specific outcomes is clearly warranted (Clarke 2017). The diversity
of non-typeableH influenzae, with some strains lacking protein D,
may limit the effect of PHiD-CVs on non-typeableH influenzae
AOM. In our review, administration of the licenced PHiD-CV10
in healthy infants was associated with non-significant 6% (95%
CI−6% to 17%) and 15% (95%CI−1% to 28%) relative reduc-
tions in the risk of all-cause AOM. The added benefit of PHiD-
CV10 over the previously licenced CRM197-PCV7 on all-cause
AOM therefore remains uncertain.
We found limited evidence that administration of PCVs during
infancy may reduce the risk of recurrent AOM. This is in line
with accumulating evidence that PCVs might disrupt the con-
tinuum of evolution from pneumococcal-associated OM towards
chronic/recurrent OM by prevention of early vaccine-serotype
AOM, thereby reducing subsequent and more complex disease
caused by non-vaccine serotypes and non-typeable H influenzae
(Ben-Shimol 2014; Dagan 2016). These findings are further sup-
ported by secondary analyses of some of the trials included in
our review indicating that licenced CRM197-PCV7 and PHiD-
PCV10 lead to fewer ventilation tubes insertions for chronic/re-
current OM (Black 2000; Palmu 2015b; Sarasoja 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current evidence from randomised controlled trials indicates that,
albeit associated with large relative risk reductions in pneumococ-
cal acute otitis media (AOM), the effect of administration of the
licenced CRM197-PCV7 and PHiD-CV10 in healthy, low-risk
infants on AOM is uncertain and modest at best. However, global
postmarketing studies of these vaccines, as well as the licenced
CRM197-PCV13, suggest that the impact (i.e. both direct and
indirect effects) of pneumococcal conjugate vaccines (PCVs) on
AOM may be substantial. Furthermore, it should be noted that
the decision whether or not to implement PCV should not come
from just AOM studies, but also from studies that see and show
the big picture, including data on invasive pneumococcal disease
such as pneumonia, bacteraemia, and meningitis.
Compared to control vaccines, PCVs were associated with an in-
crease in mild local reactions (redness, swelling), fever, and pain/
tenderness. However, we found no evidence of a difference in (far
less frequently occurring) more severe local reactions, fever, or se-
rious adverse events judged to be causally related to vaccination.
Implications for research
Since most countries across the world have implemented PCV in
nationwide immunisation programmes, future randomised con-
trolled trials comparing PCVs versus control vaccines are unlikely
to be performed. Whilst there is some observational evidence of
a difference in effects on AOM between PHiD-CV10 and the
newer CRM197-PCV13 (Gisselsson-Solen 2017), future trials
may compare the efficacy of various types of PCVs. More impor-
tantly, future research will likely shed a light on the effects of other
vaccines to prevent AOM, including (protein-based) vaccines di-
rected at Streptococcus pneumoniae (NCT01545375), as well as
other pathogens including non-typeable Haemophilus influenzae
and Moraxella catarrhalis (Pettigrew 2017).
Whether any decline in AOM will continue or wane over time
due to replacement is relevant and deserves ongoing monitor-
ing. Besides a reduction of nasopharyngeal vaccine-type serotypes,
which is presumed to induce herd effects, replacing pneumococcal
serotypes may not only lead to replacement disease in vaccines,
but also in the population. Continuing surveillance of nasopha-
ryngeal carriage and pneumococcal disease in both the short and
long term (Spijkerman 2012), in different settings and geographic
locations, is therefore of utmost importance.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Black 2000
Methods Randomised: yes, at individual level
Design: standard parallel-group design
Intention-to-treat: yes
Follow-up: 6 to 31 months
Participants N: 37,868 healthy infants
Age: 2 months
Setting: 23 medical centres within Northern California Kaiser Permanente (NCKP),
USA
Inclusion criteria: healthy children aged 2 months
Exclusion criteria: children with sickle cell disease, known immunodeficiency, any se-
rious chronic or progressive disease, a history of seizures, or a history of either pneumo-
coccal or meningococcal disease
Baseline characteristics: not described
Interventions Children were randomly allocated to either CRM197-PCV7 or a meningococcus type
C conjugate vaccine (10 µg of group C oligosaccharide conjugated to carrier protein
CRM197; MenC) at 2, 4, 6 and 12 to 15 months of age
Tx: CRM197-PCV7; N = 18,927 received 1 dose or more of the vaccine (unclear how
many children were included in otitis media analyses)
C:MenC; N= 18,941 received 1 dose ormore of the vaccine (unclear howmany children
were included in otitis media analyses)
Additional vaccines: routine childhood vaccines were administered at the recommended
ages: DTwP or DTaP; oral poliovirus vaccine or inactivated poliovirus vaccine; Hib;
hepatitis B; measles-mumps-rubella vaccine; varicella
Initially all participants received a vaccine combining Haemophilus b conjugate and
DTwP into the opposite leg and oral poliovirus vaccine concurrently. When recommen-
dations changed, the protocol was amended to allow administration of DTaP and inac-
tivated poliovirus vaccine. Vaccines not given concomitantly were given at least 2 weeks
apart from study vaccine
Outcomes Primary outcome: invasive pneumococcal disease caused by vaccine serotypes
Secondary outcomes: number of otitis media episodes in fully vaccinated per protocol;
number of otitismedia visits; time to recurrent otitis media (defined as 3 ormore episodes
in 6 months or 4 or more in 12 months); number of tympanostomy tubes placements;
number of cases of spontaneously draining ruptured tympanic membranes with culture
of a vaccine serotype pneumococcus; safety (local and systemic reactions at 48 to 72
hours after vaccination, uncommon events requiring medical attention 30 days and 60
days after vaccination, and mortality)
Clinical diagnoses of AOM were obtained from computerised data sources using diag-
noses registered by emergency physicians and paediatricians in the NCKP population.
Each clinic visit constituted a new episode unless it was classified as a follow-up visit. A
visit < 21 days after another otitis media visit was always considered a follow-up visit.
A visit 42 days or more after the most recent otitis media visit was considered a new
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Black 2000 (Continued)
episode. Visits occurring between 21 and 42 days, if the appointment was made < 3 days
in advance, were considered new episodes
Funding sources The study was supported by an unrestricted grant from Wyeth(-Ayerst); authors were
employed at Kaiser Permanente Vaccine Study Center (Oakland), Wyeth Lederle Vac-
cines and Pediatrics (Pearl River), University of Pennsylvania (Philadelphia), and Van-
derbilt University Medical Center (Nashville)
Declarations of interest Not described; authors were employed at Kaiser Permanente Vaccine Study Center (Oak-
land), Wyeth Lederle Vaccines and Pediatrics (Pearl River), University of Pennsylvania
(Philadelphia), and Vanderbilt University Medical Center (Nashville)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not described
Allocation concealment (selection bias) Unclear risk No method of allocation concealment de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Indicated as a double-blind study, but in-
sufficient details provided to ensure blind-
ing of participants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clinical diagnoses of AOM were obtained
from computerised data sources using di-
agnoses registered by emergency physicians
and paediatricians (non-trialists)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear how many children were included
in otitis media analyses
Selective reporting (reporting bias) Unclear risk Study protocol is not available. Otitis me-
dia endpoint (efficacy against otitis media
episodes) is reported as a secondary end-
point
Other bias Unclear risk Study enrolment was stopped as a result of
prespecified interim analysis
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Dagan 2001
Methods Randomised: yes, at individual level
Design: standard parallel-group design
Intention-to-treat: no, per-protocol analysis
Follow-up: 2 years starting 1 month after complete immunisation
Participants N: 264 healthy infants (261 children were included in clinical follow-up)
Age: 12 to 35 months
Setting: 8 day-care centres in Beer-Sheva, Israel
Inclusion criteria: healthy children aged 12 to 35 months
Exclusion criteria: children who had received any vaccine within the previous 4-week
period, or who were scheduled to receive any vaccine during the 4 weeks after the
administration of the study vaccines, or who had received immunoglobulin within 8
weeks of study vaccination; known or suspected impairment of immunologic functions;
major congenital malformation or serious chronic disease; known hypersensitivity to any
components of the study vaccine; previous severe vaccine-associated adverse reaction;
previous vaccination with any pneumococcal or meningococcal vaccine; febrile illness
(rectal temperature 38 °C) within 72 h before vaccination
Baseline characteristics: described and balanced (Table 1 of trial publication)
Interventions Children were randomly allocated to either CRM197-PCV9 or MenC. Children aged
12 to 17 months at time of enrolment received 2 intramuscular injections 2 to 3 months
apart, and those 18 to 35months at time of enrolment received 1 intramuscular injection
Tx: CRM-197-PCV9; N = 131
C: MenC; N = 130
Additional vaccines: not described
Outcomes Primary outcome: nasopharyngeal carriage of Streptococcus pneumoniae of the serotypes
found in the vaccines in general and antibiotic-resistant S pneumoniae in particular
Secondary outcomes: parent-reported respiratory infections including otitis media, tol-
erance (tenderness, local and systemic reactions after vaccination including erythema,
induration, and fever)
18 encounters were planned for each child during the 2-year follow-up period. Encoun-
ters were planned to take place monthly during the first year and bimonthly during the
second year. At each visit the parents were questioned about illness and antibiotic use
since the last visit. Illness episodes were divided into 4 categories:
(1) upper respiratory infections; (2) lower respiratory problems; (3) otitis media; and
(4) other illnesses. Only episodes starting 1 month after complete immunisation were
counted
Funding sources The study vaccines were provided byWyeth-LederleVaccines and Pediatrics (Pearl River,
NY)
Declarations of interest Not described
Notes Participants lost to follow-up during first 12 months:total: 32/261 (12.3%)
Participants lost to follow-up during first 12 months:Tx: 16/131 (12.2%)
Participants lost to follow-up during first 12 months:C: 16/130 (12.3%)
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not described. Block randomisation (n = 6)
stratified by DCC and age
Allocation concealment (selection bias) Low risk Randomisation list provided in a sealed en-
velope by Wyeth-Lederle Vaccines
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk PCV9 andMenC vaccines dissimilar in ap-
pearance. 2 nurses not belonging to the
study team injected the vaccines. Theywere
not allowed to reveal the child’s allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Parental interview. A positive report of OM
was defined as an episode
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up rates reported in Table 1. 12%
of children followed up for < 12 months
Selective reporting (reporting bias) Unclear risk Study protocol is not available.
Other bias Low risk No other sources of bias identified.
Eskola 2001
Methods This trial was part of a study including Kilpi 2003 (FinOM Vaccine Trial). Both Eskola
2001 and Kilpi 2003 used the same control group (hepatitis B vaccine containing 5
µg of recombinant hepatitis B surface protein) but a different treatment group, each
with a different PCV7 type. Eskola 2001 used CRM197-PCV7, while Kilpi 2003 used
OMPC-PCV7.
Randomised: yes, at individual level
Design: standard parallel-group design
Intention-to-treat: yes, both ITT and per-protocol analysis described
Follow-up: 22 consecutive months (children were followed up to 24 months of age)
Participants N: 1662 healthy infants
Age: 2 months
Setting: 8 study clinics in the communities of Tampere, Kangsala, and Nokia, Finland
Inclusion criteria: healthy children aged 2 months
Exclusion criteria: not described
Baseline characteristics: described and balanced (Table 1 of trial publication)
Interventions Children were randomly allocated to either CRM197-PCV or a hepatitis B vaccine at
2, 4, 6 and 12 to 15 months of age
Tx: CRM197-PCV; N = 831 (N = 786 completed the follow-up as specified in the
protocol)
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C: hepatitis B vaccine; N = 831 (N = 794 completed the follow-up as specified in the
protocol)
Additional vaccines: a combination vaccine containing whole-cell DTP and Hib was
given in the child’s opposite thigh at the same visit as the pneumococcal vaccine at 2,
4, and 6 months of age. In half of the study clinics, the carrier protein in the DTP
and Haemophilus influenzae vaccine was CRM197, and in the other half it was tetanus
toxoid. Inactivated poliovirus vaccine was given at 7 months of age and again at the
same time as the fourth dose of the study vaccine at 12 months of age. Measles-mumps-
rubella vaccine was administered at 18 months
Outcomes Primary outcome: number of AOM episodes due to the pneumococcal serotypes in-
cluded in the vaccine
Secondary outcomes: number of all-cause AOM episodes, culture-confirmed and
pathogen-specific AOM episodes; preventing first and subsequent AOM episodes; num-
ber of children with recurrent AOM episodes (defined as 3 or more AOM episodes in
the last 6 months or 4 or more in the last 12 months); serious adverse events, safety
(pain, local and systemic reactions within 3 days after vaccination, unexpected events
after vaccination and mortality)
All children attended 1 of the study clinics for enrolment at 2months of age and thereafter
at 4, 6, 7, 12, 13, 18, and 24 months. Parents were encouraged to bring their child to
the study clinic for evaluation of symptoms suggesting respiratory infection or AOM.
AOM was diagnosed by otoscopy (visibly abnormal tympanic membrane in terms of
colour, position, or mobility, suggesting middle ear effusion) and the presence of at
least 1 of the following symptoms or signs of acute infection: fever, earache, irritability,
diarrhoea, vomiting, acute otorrhoea not caused by otitis externa, and other symptoms
of respiratory infection.
For the overall and pathogen-specific AOM episodes, a new episode was considered to
have started if at least 30 days had elapsed since the beginning of the previous episode.
For AOM episodes according to serotype, a new episode was considered to have started
if 30 days had elapsed since the beginning of an episode due to the same serotype, or if
any interval had elapsed since the beginning of an episode due to a different serotype. If
more than 1 serotype was recovered from the middle ear fluid at the same time, only 1
episode was considered to have started
Funding sources Supported by Merck, Pasteur Mérieux Connaught, and Wyeth-Lederle Vaccines and
Pediatrics
Declarations of interest Dr Eskola and Dr Kilpi have served as consultants to Wyeth-Lederle Vaccines
Notes Participants lost to follow-up:total: 82/1662 (4.9%) did not complete the follow-up
period specified in the protocol
Participants lost to follow-up:Tx: 45/831 (5.4%) did not complete the follow-up
period specified in the protocol
Participants lost to follow-up:C:37/831 (4.5%) did not complete the follow-up period
specified in the protocol
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk 6 letters corresponding to the 3 treatment
options were randomly allocated to consec-
utive participant identification numbers,
using an allocation of 1:1:1 and a block size
of 12 (see Kilpi 2003).
Allocation concealment (selection bias) Low risk Individual treatment assignments were
kept in sealed envelopes until vaccination
(see Kilpi 2003).
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Use of vaccinators who were not otherwise
involved in the trial follow-up. Letter code
was destroyed immediately after vaccina-
tion (see Kilpi 2003).
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessment of the outcome was done ac-
cording to a strict definition of AOM. As-
sessment was done by personnel other than
those who vaccinated the children (vacci-
nators were not otherwise involved in the
trial follow-up) (see Kilpi 2003).
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for dropout or lost to follow-up,
or both not reported. Not expected to have
major impact on outcome since 94.6%
in the CRM197-PCV7 and 95.5% in the
control group completed the follow-up as
specified in the protocol
Selective reporting (reporting bias) Unclear risk Prespecified outcomes (primary and sec-
ondary) are listed in ClinicalTrials.gov (al-
though uploaded after study end)
Other bias Low risk No other sources of bias identified.
Jansen 2008
Methods Randomised: yes, at individual level
Design: standard parallel-group design
Intention-to-treat: yes
Follow-up: follow-up started 14 days after the second set of vaccinations and continued
for 6 to 18 months, depending on the year of inclusion
Participants N: 597 children with a previously diagnosed RTI
Age: 18 to 72 months
Setting: GPs in the centre of the Netherlands selected children
Inclusion criteria: children aged 18 to 72 months with a previously diagnosed RTI
registered according to the ICPC, i.e. AOM; cough (with fever); acute upper RTI; acute
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laryngitis/tracheitis; acute bronchitis/bronchiolitis; influenza; pneumonia; pleurisy/pleu-
ral effusion
Exclusion criteria: children with chronic asthma or recurrent wheezing (for longer than
3 months) treated with corticosteroids; craniofacial abnormalities; clinically significant
hypersensitivity to eggs; previous serious adverse reactions to vaccines; previous influenza,
pneumococcal, or hepatitis B vaccinations and those with conditions for which these
vaccinations are already recommended, such as chronic cardiac and respiratory conditions
Baseline characteristics: described and balanced (Table 1 of trial publication)
Interventions Childrenwere randomly allocated to either TIV/PCV7, TIV/placebo (TIV plus standard
diluent (0.9% phosphate buffered NaCl)) or HBV/placebo (recombinant HBV vaccine-
Engerix B Junior plus placebo vaccine). Strains in the TIV 2003-2004 formulation were
H1N1, H3N2, and B/HongKong/330/01; strains in the TIV 2004-2005 formulation
were H1N1, H3N2, and B/Shanghai/361/2002; strains in the TIV 2005-2006 formu-
lation included H1N1, H3N2, and B/Shanghai/361/2002
Children received 2 vaccinations 4 to 8 weeks apart in the first year of inclusion, and the
first 2 cohorts of children received a subsequent vaccination in the subsequent year
Tx: TIV/CRM197-PCV7; N = 197 (N = 163 completed; 67,867 person-days analysed,
14% missing)
C1: TIV/placebo; N = 187 (N = 148 completed; 60,515 person-days analysed, 20%
missing)
C2: HBV/placebo; N = 195 (N = 160 completed; 67,679 person-days analysed, 15%
missing)
Additional vaccines: not described
Outcomes Primary outcome: febrile RTI, defined as fever (tympanic temperature 38.0 °C) for
at least 2 consecutive days accompanied by 1 or more of the aforementioned signs or
symptoms of RTI with a moderate or severe severity score
Secondary outcomes: febrile RTI-related PCR-confirmed influenza, GP visits, antibi-
otic prescriptions, or a physician-diagnosed episode of AOM, tolerability and safety
Each parent was instructed to keep a daily diary, recording any clinical signs or symptoms
associated with RTI and to characterise their severity on a scale of 1 (mild) to 3 (severe).
The parent was also instructed to measure the child’s body temperature using a validated
electronic tympanic thermometer, and was asked to record all GP visits due to their
child’s RTI-related complaints. For each such visit, the GP was instructed to complete a
form including information on the diagnosis and possible antibiotic prescriptions.
During influenza seasons, the parent was instructed to contact the trial centre for evalu-
ation for influenza if the child had fever (tympanic temperature 38.0 °C) for more than
1 day accompanied by at least 1 RTI-associated sign or symptom of severity score 2. A
trained research assistant obtained a nasopharyngeal swab for viral determination within
4 days of onset of fever and symptoms. Each sample was analysed by real-time PCR for
the presence of influenza A and B viruses
Funding sources The study was funded by the Netherlands Organisation for Health Research and Devel-
opment (ZonMw). The funding agency played no role in the design and conduct of the
study; the collection, analysis, and interpretation of the data; or the preparation, review,
or approval of the manuscript
Influenza vaccines were provided by Solvay, Weesp, the Netherlands. Pneumococcal
vaccines were provided byWyethVaccines Research, Berkshire, UK.Hepatitis B vaccines
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were provided by GlaxoSmithKline BV, Rixensart, Belgium
Declarations of interest The authors declared no conflicts of interest.
Notes Participants lost to follow-up:total: 108/579 (18.7%) completely (N = 41) or partially
(N = 67) lost to follow-up
Participants lost to follow-up:Tx: 34/197 (17.3%) completely (N = 8) or partially (N
= 26) lost to follow-up; 67,867 person-days analysed, 14% missing
Participants lost to follow-up:C1: 39/187 (20.8%) completely (N = 19) or partially
(N = 20) lost to follow-up; 60,515 person-days analysed, 20% missing
Participants lost to follow-up:C2: 35/195 (17.9%) completely (N = 14) or partially
(N = 21) lost to follow-up; 67,679 person-days analysed, 15% missing
2 of the 3 treatment arms received an additional vaccination in the second year of
the study. To evaluate blinding, parents of these cohorts of children were asked which
vaccinations that they thought their child had received just after the vaccinations were
given and at the end of the study. Just after the vaccination, 87% of the parents either
did not know or identified the wrong set of vaccinations; at the end of the study, this
percentage was 80%, indicating successful blinding
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not described; children were randomly as-
signed in blocks of 3 in a 1:1:1 ratio
Allocation concealment (selection bias) Unclear risk No method of allocation concealment was
described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The injections were administered by non-
blinded research nurses who were not in-
volved in subsequent follow-up and who
were instructed not to reveal the interven-
tion allocation. The treatment group as-
signments were not revealed to parents, in-
vestigators, research personnel conducting
the follow-up, or healthcare providers, all
of whom remained blinded throughout the
study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The parents were asked to record all GP
visits due to their child’s RTI-related com-
plaints. For each such visit, the GP was
instructed to complete a form including
information on the diagnosis and possi-
ble antibiotic prescriptions. The treatment
group assignments were not revealed to
parents, investigators, and research person-
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nel conducting the follow-up or healthcare
providers, all of whom remained blinded
throughout the study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Substantial loss to follow-up (< 14% in
both groups)
Selective reporting (reporting bias) Low risk Prespecified outcomes (primary and sec-
ondary) are listed in ClinicalTrials.gov
Other bias Low risk No other sources of bias identified.
Kilpi 2003
Methods This trial was part of a study including Eskola 2001 (FinOMVaccine Trial). Both Eskola
2001 and Kilpi 2003 used the same control group (hepatitis B vaccine containing 5 µg
of recombinant hepatitis B surface protein) but a different PCV7 type. Eskola 2001 used
CRM197-PCV7, while Kilpi 2003 used OMPC-PCV7.
Randomised: yes, at individual level
Design: standard parallel-group design
Intention-to-treat: no, per-protocol analysis
Follow-up: 22 consecutive months (children were followed up to 24 months of age)
Participants N: 1666 healthy infants
Age: 2 months
Setting: 8 study clinics in the communities of Tampere, Kangsala, and Nokia, Finland
Inclusion criteria: healthy children aged 2 months
Exclusion criteria: not described
Baseline characteristics: described and balanced (Table 1)
Interventions Children were randomly allocated to either OMPC-PCV7 or a hepatitis B vaccine at
2, 4, 6 and 12 to 15 months of age. From 3 November 1997 onwards, for the children
randomised to receive OMPC-PCV7, the fourth dose of the conjugate vaccine was
replaced by PPV23, Pneumovax23 including serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V,
10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
Tx: OMPC-PCV7; N = 835 (N = 805 completed the follow-up as specified in the
protocol)
C: hepatitis B vaccine; N = 831 (N = 794 completed the follow-up as specified in the
protocol)
Additional vaccines: a diphtheria-tetanus toxoids-pertussis vaccine with a whole-cell
pertussis component, combined with aHaemophilus influenzae type b conjugate vaccine
(DTP-Hib), was administered concomitantly with the first 3 doses of the study vaccine,
and an inactivated poliovirus vaccine was administered with the fourth dose. In 4 study
clinics, the carrier protein in the DTP-Hib conjugate combination was CRM197, and
in the other 4 it was tetanus toxoid
Outcomes See Eskola 2001.
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Funding sources Supported by Aventis Pasteur, Merck, and Wyeth-Lederle Vaccines and Pediatrics
Declarations of interest Not described; from Eskola 2001: Dr Eskola and Dr Kilpi have served as consultants to
Wyeth-Lederle Vaccines
Notes Participants lost to follow-up:total: 67/1666 (4.0%) did not complete the follow-up
period specified in the protocol
Participants lost to follow-up:Tx: 30/835 (3.6%) did not complete the follow-up
period specified in the protocol
Participants lost to follow-up:C:37/831 (4.5%) did not complete the follow-up period
specified in the protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 6 letters corresponding to the 3 treatment
options were randomly allocated to consec-
utive participant identification numbers,
using an allocation of 1:1:1 and a block size
of 12
Allocation concealment (selection bias) Low risk Individual treatment assignments were
kept in sealed envelopes until vaccination
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Use of vaccinators who were not otherwise
involved in the trial follow-up. Letter code
was destroyed immediately after vaccina-
tion
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessment of the outcome was done ac-
cording to a strict definition of AOM. As-
sessment was done by personnel other than
those who vaccinated the children (vacci-
nators were not otherwise involved in the
trial follow-up)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No reporting of reasons for dropout or loss
to follow-up, or both. Not expected to have
a major impact on outcome since 96.0% in
the OMPC-PCV7 and 95.5% in the con-
trol group completed the follow-up as spec-
ified in the protocol
Selective reporting (reporting bias) Unclear risk Prespecified outcomes (primary and sec-
ondary) are listed in ClinicalTrials.gov (al-
though uploaded after study end)
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Other bias Unclear risk Mixed schedule with 187 children boosted
with PPV23.Unclear how researchers iden-
tified those allocated to OMPC-PCV7 to
receive PPV23 after November 1997
O’Brien 2008
Methods The design of this cluster-randomised trial has been described extensively in Moulton
2001, while the findings on IPD (main outcome of the trial) have been published in
O’Brien 2003.
Randomised: yes, at group level
Design: cluster-randomised design
Intention-to-treat: no, per-protocol analysis
Follow-up: depending on time of inclusion, maximum duration of follow-up 40months
Participants N: 944 (944 of the 4476 children were randomly selected for chart review. This sample
size was determined by logistic feasibility and expected frequency of healthcare events.
Of these 944 children, 856 were found to have strictly met the chart review criteria.)
Age: below 2 years of age
Setting: Navajo and White Mountain Apache region, USA
Inclusion criteria: Navajo and White Mountain Apache children below 2 years of age
Exclusion criteria: no exclusion criteria described
Baseline characteristics: balanced but data not shown
Interventions Children were randomly allocated to either CRM197-PCV7 or MenC (10 µg of group
C oligosaccharide conjugated to carrier protein CRM197). For each of the study and
control vaccines, 3 immunisation schedules were designed according to age of entry into
the trial: 6 weeks to 6 months (3 doses, ideally at 2, 4, and 6 months of age and a booster
at 12 to 15 months of age), 7 months to 11 months (2 doses 1 month apart and a booster
at 12 to 15 months of age), and 12 months to 23 months (2 doses separated by at least 2
months). Over the course of the trial, the great majority of new enrollees are in the first
group, which is referred to as the primary efficacy cohort
Tx: CRM197-PCV7; N = unknown (N = 424 analysed in primary efficacy group)
C: MenC; N = unknown (N = 432 analysed in primary efficacy group)
Additional vaccines: not described
Outcomes Primary outcome: clinically diagnosed episodes of OM
Every medical visit made by study children was evaluated through 2 years of age. OM
visits, as documented by the patients’ treating physician, were recorded
A new OM episode was counted if any of the following were recorded as the diagnosis:
OM, AOM, bilateral OM, chronic OM, OM with perforation, otorrhoea, pressure-
equalising tube placement, perforated tympanic membrane, serous OM and bullous
myringitis
An episode of AOM was categorised as either AOM or bilateral AOM. An OM episode
was categorised as severe if there were 3 or more OM visits for the episode. A child’s first
medical visit for OM was considered their first episode. OM visits occurring less than
21 days after the immediately prior otitis-related visit and visits noted as a follow-up to
a previous otitis-related visit were counted as follow-up visits, not as OM episodes
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Funding sources Financial support for the American Indian PnCRM7 Efficacy Trial was fromWyeth Vac-
cines, National Institutes of Health, World Health Organization, The National Vaccine
Program Office, and the Centers for Disease Control and Prevention
Declarations of interest Dr O’Brien and Dr Santosham participated in Wyeth Scientific Advisory Boards. Dr
O’Brien, Dr Moulton, Dr Reid, Dr Weatherholtz, and Dr Santosham received research
funding from Wyeth Vaccines
Notes Participants lost to follow-up:total: 88/944 (9.3%) not included in primary efficacy
analysis
Participants lost to follow-up:Tx: unknown
Participants lost to follow-up:C: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation using
38 independent randomisation units, strat-
ified using 3 blocks of 4 units and 13 blocks
of 2 units
Allocation concealment (selection bias) Low risk 6 labels were assigned to the vaccines (B, F,
H, M, T, U), with 3 labels for CRM197-
PCV7 and 3 for MenC. The grouping of
these codes was known only to a statistician
employed by the manufacturer (who had
no other responsibilities with respect to the
trial other than handling treatment alloca-
tion and randomisation issues). No loss of
clusters
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masked treatment assignment (vaccines
were labelled). In addition, field staff were
blinded as to serotype of the invasive dis-
ease cases, and thus did not know which
ones would be likely to be prevented by an
effective vaccine
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Every medical visit made by study chil-
dren was evaluated through 2 years of age.
OM visits, as documented by the patients’
treating physician, were recorded. Treating
physicians were blinded to treatment allo-
cation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 88 of the 944 children (9.3%) not included
inprimary efficacy analysis; no information
provided on the distribution across treat-
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ment groups
Selective reporting (reporting bias) Low risk Study design was described extensively in
Moulton 2001 and O’Brien 2003.
Other bias Unclear risk Study enrolment was stopped as a result of
prespecified interim analysis
Prymula 2006
Methods Randomised: yes, at individual level
Design: standard parallel-group design
Intention-to-treat: yes, both ITT and per-protocol analysis described
Follow-up: efficacy follow-up started on the day of the first dose of study vaccine (for
ITT analysis) or 2 weeks after the third vaccine dose (for the per-protocol analysis) and
continued until 24 to 27 months of age
Participants N: 4968 healthy infants
Age: between 6 weeks and 5 months
Setting: 27 paediatric centres in the Czech Republic and 23 in Slovakia
Inclusion criteria: healthy children aged between 6 weeks and 5 months with no acute
illness
Exclusion criteria: use of any investigational or non-registered drug or vaccine other
than the study vaccines within 30 days preceding first dose of the study vaccines; previous
vaccination against Streptococcus pneumoniae; fever (defined as a rectal temperature of 38
°C or higher or temperature by other routes of 37.5 °C or higher); history of allergic
disease or reactions likely to be exacerbated by any component of the study vaccines;
other conditions that might have potentially interfered with the interpretation of study
outcomes according to the investigator
Baseline characteristics: described and balanced (Table 1 of trial publication)
Interventions Children were randomly allocated to either PHiD-CV11 or a hepatitis A vaccine (con-
taining 720 ELISA units of inactivated hepatitis A virus antigen (strain HM 175)) at
about 3, 4, 5 and 12 to 15 months of age
Tx: PHiD-CV11; N = 2489 (N = 2455 included in per-protocol cohort for efficacy)
C: hepatitis A vaccine; N = 2479 (N = 2452 included in per-protocol cohort for efficacy)
Additional vaccines: a concomitant hexavalent diphtheria-tetanus-3-component acel-
lular pertussis-hepatitis B-inactivated poliovirus types 1, 2, and 3Haemophilus influenzae
type b (DTPa-HBV-IPV/Hib) vaccine was offered to all study participants, followed by
a booster dose at age 15 to 18 months
Outcomes Primary outcome: first episode of AOM caused by vaccine pneumococcal serotypes
Secondary outcomes: first episode of AOM caused by non-typeable Haemophilus in-
fluenzae, any all-cause AOM episodes, any vaccine-type AOM episodes, any cross-reac-
tive serotypes AOM, any non-vaccine-type AOM, safety (adverse events arising within
31 days of vaccination and serious adverse events occurring throughout the study period)
There was no active surveillance. Unscheduled doctor visits could take place any time
during follow-up according to standard local practice (parents consulting their local
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paediatrician in case of illness of their child). Parents were advised to consult their
paediatrician if their child was sick, had ear pain, or had spontaneous ear discharge.
Children with suspected AOM were immediately referred to ENT surgeons
AOM was defined as either abnormal findings of the tympanic membrane at otoscopy
(i.e. redness, bulging, loss of light reflex) or the presence of middle ear effusion as shown
by simple or pneumatic otoscopy or by microscopy together with at least 2 of the fol-
lowing signs or symptoms: ear pain, ear discharge, hearing loss, fever, lethargy, irritabil-
ity, anorexia, vomiting, or diarrhoea. These signs or symptoms had to be present for a
maximum of 14 days
For patients with repeated doctor visits, a new episode of AOM was judged to have
started if more than 30 days had elapsed since the beginning of the previous episode.
Additionally, for categories defined according to bacterial pathogen or serotype, a new
episode was judged to have started if any interval had elapsed since the beginning of an
episode caused by a different bacterial pathogen or serotype
Recurrent AOM was defined as 3 or more AOM episodes in the last 6 months or 4 or
more in the last 12 months
Funding sources The study was supported by GlaxoSmithKline Biologicals, Rixensart, Belgium
Declarations of interest Dr Prymula is a consultant to GlaxoSmithKline and other pharmaceutical companies,
and has received travel grants or honoraria paid by healthcare companies within the past
3 years. 7 co-authors are employees of GlaxoSmithKline Biologicals, of which 4 own
shares in GlaxoSmithKline
Notes Participants lost to follow-up:total: 61/4968 (1.2%) did not complete the follow-up
period specified in the protocol
Participants lost to follow-up:Tx: 34/2489 (1.4%) did not complete the follow-up
period specified in the protocol
Participants lost to follow-up:C: 27/2479 (1.1%) did not complete the follow-up
period specified in the protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random list
Allocation concealment (selection bias) Low risk Randomisation (1:1) was done with a
study-specific central randomisation sys-
tem via the internet which, on receipt of the
infant’s initials and birth date, determined
the vaccine number to be used
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Indicated as a double-blinded study. The
sponsor numbered the vaccine supplies.
However, it is unknown whether the ap-
pearance of the vaccines was similar at the
time of administration
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Visits during efficacy follow-up were ac-
cording to standard local clinical practice.
When AOM was suspected, children were
referred to ENT surgeons
Incomplete outcome data (attrition bias)
All outcomes
Low risk No reporting of reasons for dropout or loss
to follow-up, or both. Not expected to have
a major impact on outcome since 98.6% in
the PHiD-CV11 and 98.9% in the control
group completed the follow-up as specified
in the protocol
Selective reporting (reporting bias) Low risk Prespecified outcomes (primary and sec-
ondary) are listed in ClinicalTrials.gov
Other bias Low risk Study enrolment was stopped as a result
of prespecified interim analysis. No other
sources of bias identified
Tregnaghi 2014
Methods This trial was part of Clinical Otitis Media and Pneumonia Study (COMPAS; clini-
caltrials.gov/show/NCT00466947) to assess the efficacy of PHiD-CV10 against IPD,
CAP, and AOM in young Latin American children
Randomised: yes, at individual level
Design: standard parallel-group design
Intention-to-treat: yes, both ITT and per-protocol analysis described
Follow-up: total follow-up duration 4 years
Participants N: 23,821 healthy infants (for Panama, AOM cohort: 7359)
Age: mean age 9 months
Setting: well-baby clinics at 5 sites (3 in Argentina, 1 in Colombia, and 1 in Panama);
all countries are classified as upper-middle economies
Inclusion criteria: healthy children aged 6 to 16 weeks
Exclusion criteria - use or planned use of any investigational or unregistered drug or
vaccine other than the study vaccines; previous vaccination against diphtheria, tetanus,
pertussis, Haemophilus influenzae type b, hepatitis A, and/or Streptococcus pneumoniae;
history of allergic disease or reactions likely to be exacerbated by any components of
the study vaccines; acute disease at time of enrolment; low birthweight (< 2500 g) not
permitted for Colombia
Baseline characteristics: described and balanced (Table 3 of trial publication)
Interventions Children were randomly allocated either to PHiD-CV10 or a hepatitis B vaccine at 2,
4, and 6 months followed by 1 dose of PHiD-CV10 or hepatitis A vaccine at 15 to 18
months of age
Tx: PHiD-CV10; N = 11,875 (N = 10,295 completed the follow-up as specified in the
protocol); for AOM cohort N = 3602 (N = 3010 completed the follow-up as specified
in the protocol)
42Pneumococcal conjugate vaccines for preventing acute otitis media in children (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tregnaghi 2014 (Continued)
C: hepatitis B vaccine; N = 11,863 (N = 10,201) completed the follow-up as specified
in the protocol); for AOM cohort N = 3612 (N = 2979 completed the follow-up as
specified in the protocol)
Additional vaccines: a combination vaccine containing diphtheria-tetanus-acellular per-
tussis-inactivated polio and Haemophilus influenzae type b (DTPa-IPV/Hib) was given
in the child’s opposite thigh at the same visit as the pneumococcal vaccine at 2, 4, 6 and
15 to 18 months
Outcomes Primary outcome - likely bacterial CAP
Secondary outcomes: other CAP outcomes, first episode of clinically confirmed AOM,
first episode of pathogen-specific AOM, serious adverse events and mortality occurring
throughout the study period
The AOM outcome was studied in Panama only (7357 of the 23,821 randomised
children)
Initially, AOM cases were captured only when parents sought medical attention for
children with AOM symptoms. However, because of a lower-than-expected AOM rate,
the surveillance was enhanced in July 2009 (2 years after start of enrolment) through
regular telephone calls or home visits by study personnel who advised parents to visit the
clinic if their child had symptoms suggestive of AOM. If the physician suspected AOM,
the child was referred to one of the ENT surgeons involved in the trial
Clinically confirmed AOM was defined as either altered visual appearance of the tym-
panic membrane (e.g. redness, bulging, loss of light reflex) or the presence of middle ear
effusion (by pneumatic otoscopy or otomicroscopy). A recent onset (duration less than
5 days) of at least 2 of the following clinical symptoms was also required: ear pain, ear
discharge, hearing loss, fever, lethargy, irritability, anorexia, vomiting, or diarrhoea
The severity of each AOM episode (mild, moderate, severe) was assessed by combining
objective elements of the Friedman scale (the Ear Treatment Group-five items (ETG-5)
and otoscopy scale with eight grades of severity (OS-8)) with subjective elements in a
clinical otologic scale
When middle ear fluid was suspected, tympanocentesis was performed and bacterial
presence was assessed by culture
Funding sources Sponsored by GlaxoSmithKline Biologicals, the vaccine developer and manufacturer.
The data generated in the trial are subject to a confidentiality agreement between the
investigators and the sponsor that allowed the investigators full access to the study data
and included an obligation for GlaxoSmithKline Biologicals to permit publication with-
out excessive delay
Declarations of interest Dr Sáez-Llorens declares having received financial support from the study sponsor for
travel tomeetings, andhis institution received grants fromHealthResearch International.
Drs López and Calvo declare their institutions received support for travel to meetings
and grants from the study sponsor. Dr Calvo declares her institution received consulting
fee/honorary from the study sponsor. Dr Hausdorff is a patent coholder of PCV13 (no
royalties). 9 co-authors are employees of GlaxoSmithKline companies and own stock/
stock options from the GlaxoSmithKline group of companies
Notes Participants lost to follow-up:total: 592/3602 (16.4%) did not complete the follow-
up period specified in the protocol
Participants lost to follow-up:Tx: 633/3612 (17.5%) did not complete the follow-up
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period specified in the protocol
Participants lost to follow-up:C: 1225/7214 (17.0%) did not complete the follow-up
period specified in the protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomization list was gen-
erated by the sponsor using a standard
SAS (SAS Institute) program and was used
to number the vaccines. A randomiza-
tion blocking scheme was used to ensure
that balance between treatment groups was
maintained”
Allocation concealment (selection bias) Low risk Quote: “Vaccine allocation at each site
was performed using a central randomiza-
tion system on the Internet (SBIR, Glax-
oSmithKline Vaccines), and treatment was
concealed from all study personnel”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Vaccines were numbered by the sponsor,
and treatment allocation was concealed
from study personnel. There were minor
differences in vaccine appearance, but vac-
cines were prepared and administered by
personnel who took no further part in the
study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Vaccines were prepared and administered
by personnel who took no further part in
the study. Parents/guardians of participat-
ing children and study personnel involved
in data gathering, processing, and analysis
and safety assessment were blind to vaccine
allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Almost all randomised children were in-
cluded in ITT analysis
Selective reporting (reporting bias) Low risk Prespecified outcomes listed in clinicaltri-
als.gov/show/NCT00466947
Other bias Low risk No other sources of bias identified.
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van Kempen 2006
Methods This study was performed in parallel with Veenhoven 2003 (OMAVAX-trial), but anal-
ysed separately due to differences in study population
Randomised: yes, at individual level
Design: standard parallel-group design
Intention-to-treat: unclear
Follow-up: 26 months
Participants N: 74 children with a history of AOM
Age: between 1 and 7 years
Setting: ENT department of the Ghent University Hospital in Belgium
Inclusion criteria: children aged 1 to 7 years with a history of AOM defined as at least
2 separate clinically diagnosed AOM episodes in the past year
Exclusion criteria: children with any underlying illnesses including immunocompro-
mising conditions other than partial serum IgA and IgG2 deficiencies, craniofacial ab-
normalities, previous pneumococcal vaccination, or documented hypersensitivity to any
of the vaccine components
Baseline characteristics: described and balanced (Table 1 of trial publication)
Interventions Children were randomly allocated to either a CRM197-PCV7 or a hepatitis A vaccine
(containing 720 units of inactivated hepatitis A virus). Children aged 12 to 24 months
received 2 intramuscular injections with a 1-month interval, and those aged over 2 years
received 1 intramuscular injection. Those allocated to CRM197-PCV7 additionally
received PPV23 6 months (in children aged 12 to 24 months) or 7 months (in those
aged over 2 years) later
Tx: CRM197-PCV7 plus PPV23; N = 38 (N = 35 completed the vaccination scheme)
C: hepatitis A vaccine; N = 36 (N = 33 completed the vaccination scheme)
Additional vaccines: not described
Outcomes Primary outcome: number of AOM episodes during 18-month follow-up
Secondary outcomes: immunogenicity; nasopharyngeal carriage of conjugate vaccine-
related serotypes; and antibiotic-resistant pneumococci
At scheduled hospital visits at 7, 14, 20, and 26 months after randomisation, a medical
historywas taken, antibiotic usage noted, and an otomicroscopic examinationperformed.
When, at least 1 month following complete vaccination, a new AOM episode was sus-
pected, parents were asked to bring their sick child within 24 hours to the study centre
for otoscopic diagnosis. In case of all other AOM episodes during follow-up, participants
were allowed to visit the study centre, their family physician, or a paediatrician, who was
asked to report otoscopic findings, diagnosis, and treatment on an AOM registration
form
AOMwas defined by an abnormal tympanic membrane on otomicroscopy (red, dull, or
bulging) plus at least 1 of the following symptoms or signs of acute infection: earache,
acute otorrhoea, fever (> 38.5 °C rectally), or irritability
Funding sources The study was supported by the Netherlands Organisation for Health Research and
Development (ZonMw) and the Dutch Health Insurance Company Zilveren Kruis-
Achmea as part of the OMAVAX-trial. Wyeth-Lederle Vaccines and Pediatrics provided
the pneumococcal vaccines, and GlaxoSmithKline provided the hepatitis A vaccines
Declarations of interest The authors declared no conflicts of interest.
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van Kempen 2006 (Continued)
Notes Participants lost to follow-up:total: 6/74 (8.1%) did not complete the follow-up period
specified in the protocol
Participants lost to follow-up:Tx: 3/38 (7.9%) did not complete the follow-up period
specified in the protocol
Participants lost to follow-up:C: 3/36 (8.3%) did not complete the follow-up period
specified in the protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not described, randomisation stratified ac-
cording to age (12 to 24 months versus
25 to 84 months) and number of previous
AOM episodes per year (2 to 3 versus 4 or
more episodes)
Allocation concealment (selection bias) Low risk 2 study nurses immunised all children ac-
cording to a randomisation list provided
to them in a sealed envelope by a third
party (the Julius Center for Health Sci-
ences, Utrecht, the Netherlands)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The nurses that vaccinated children were
not allowed to reveal the child’s allocation
to either the study team or the parents
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk When a new AOM episode was suspected,
parents were asked to bring their sick child
within 24 hours to the study centre for
otoscopic diagnosis. In case of all other
AOM episodes during follow-up, partici-
pants were allowed to visit the study centre,
their family physician, or a paediatrician,
whowas asked to report otoscopic findings,
diagnosis, and treatment on an AOM reg-
istration form
Incomplete outcome data (attrition bias)
All outcomes
Low risk In total, 6 of the 74 children (8.1%) did
not complete the follow-up period spec-
ified in the protocol (equally distributed
across groups). Reasons for withdrawals are
described in the Results section of the arti-
cle
Selective reporting (reporting bias) Unclear risk No study protocol available.
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van Kempen 2006 (Continued)
Other bias Low risk No other sources of bias identified.
Veenhoven 2003
Methods This study was performed in parallel with van Kempen 2006, but analysed separately
due to differences in study population
Randomised: yes, at individual level
Design: standard parallel-group design
Intention-to-treat: yes
Follow-up: 18 months, starting 1 month after completion of the vaccination scheme
Participants N: 383 children with a history of AOM
Age: between 1 and 7 years
Setting: a general hospital (Spaarne Hospital, Haarlem) and a tertiary care hospital (Wil-
helmina Children’s Hospital of the University Medical Centre Utrecht) in the Nether-
lands
Inclusion criteria: children aged 1 to 7 years with a history of AOMdefined as 2 or more
AOM episodes in the year before study entry. The number of previous AOM episodes
was based on parental report and on clinical confirmation of the diagnosis by a physician
Exclusion criteria: children with immunodeficiency, cystic fibrosis, immotile cilia syn-
drome, craniofacial abnormalities, chromosomal abnormalities such as Down’s syn-
drome, and severe adverse events during previous vaccinations
Baseline characteristics: described and balanced (Table 1 of trial publication)
Interventions Children were randomly allocated to either CRM197-PCV7 followed by a PPV23 or a
hepatitis A or B vaccine
Children aged 12 to 24 months in the pneumococcal vaccination group received PCV7
twice with a 1-month interval, followed 6 months later by PPV23. The control vaccine
group received 3 hepatitis B vaccinations (Engerix-B) according to a similar time schedule
Children aged 25 to 84 months in the pneumococcal vaccine group received 1 dose
of PCV7 followed 7 months later by PPV23. The control group received hepatitis A
vaccine (Havrix) twice
Tx: CRM197-PCV7 plus PPV23; N = 190 (N = 190 included in ITT analysis)
C: hepatitis A or hepatitis B vaccine; N = 193 (N = 193 included in ITT analysis)
Additional vaccines: not described
Outcomes Primary outcome: number of clinical AOM episodes during 18-month follow-up
Secondary outcomes: number of AOM episodes due to the 7 pneumococcal serotypes
included in the PCV7 vaccine and nasopharyngeal carriage of conjugate vaccine
serotypes, serious adverse events
Parents were instructed to visit the study clinics or their GP, ENT surgeon, or paedia-
trician to assess symptoms suggesting AOM. Physicians registered signs and symptoms
of every AOM episode on standard registration forms and were unaware of treatment
allocation. AOM was defined according to the guideline issued by the Dutch College
of General Practitioners, i.e. presence of an abnormal tympanic membrane on otoscopy
(red, dull, or bulging) or otorrhoea and at least 1 of the following signs or symptoms of
acute infection: acute earache, new-onset otorrhoea, irritability, or fever greater than 38.
5 °C rectally or 38.0 °C axillary
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Veenhoven 2003 (Continued)
Funding sources The study was supported by the Netherlands Organisation for Health Research and
Development (ZonMw) and the Dutch Health Insurance Company Zilveren Kruis-
Achmea as part of the OMAVAX-trial. Wyeth-Lederle Vaccines and Pediatrics provided
the pneumococcal vaccines, and GlaxoSmithKline provided the hepatitis A vaccines
Declarations of interest The authors declared no conflicts of interest.
Notes Participants lost to follow-up:total: 1/383 (0.3%); all children included in ITT analysis
Participants lost to follow-up:Tx: 0/190 (0%)
Participants lost to follow-up:C: 1/193 (0.5%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Table of random numbers that identified
the vaccine scheme, randomisation strati-
fied according to age (12 to 24 months ver-
sus 25 to 84 months) and number of previ-
ous AOM episodes per year (2 to 3 versus
4 or more episodes)
Allocation concealment (selection bias) Unclear risk No method of allocation concealment was
described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Vaccine was administered to the child by a
study nurse, so that parents and physicians
were unaware of treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Parents were instructed to visit the study
clinics or their family physician, otolaryn-
gologist, or paediatrician to assess symp-
toms suggesting AOM. Physicians regis-
tered signs and symptoms of every AOM
episode on standard registration forms
and were unaware of treatment allocation.
AOM was defined according to the guide-
line issued by theDutch College of General
Practitioners
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised children were included in
ITT analysis.
Selective reporting (reporting bias) Unclear risk No study protocol available.
Other bias Low risk No other sources of bias identified.
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Vesikari 2016
Methods This trial was nested within the Finnish invasive pneumococcal disease vaccine trial
(FinIP; clinicaltrials.gov/show/NCT00861380; Palmu 2013), a cluster-randomised dou-
ble-blind trial to assess the efficacy of PHiD-CV10 against IPD, all-cause antibiotic-
purchases, tympanostomy tube placements, and vaccine-preventable diseases
Randomised: yes, at cluster level
Design: parallel-group (4 groups) design
Intention-to-treat: no, per-protocol analysis
Follow-up - mean duration of follow-up 18 months
Participants N:- 5095 healthy infants
Age: mean age at first dose 2.3 months
Setting: 15 study centres in Finland
Inclusion criteria: healthy children aged 6 weeks to 18 months
Exclusion criteria: prior administration of pneumococcal vaccine, hepatitis A or B
vaccine, any investigational or non-registered product, contraindication to immunisation
Baseline characteristics: described and balanced (Suppl. Table 1)
Interventions Children were randomly allocated (2:2:1:1) to either PHiD-CV10 3 + 1, 2 + 1, control
3 + 1, control 2 + 1 (control vaccine was hepatitis B for children aged < 12 months or
hepatitis A for those aged 12 months or above)
Tx1: PHiD-CV10 3 + 1; N = 1846 (N = 1846 completed the follow-up as specified in
the protocol)
Tx2: PHiD-CV10 2 + 1; N = 1313 (N = 942 completed the follow-up as specified in
the protocol)
C1: hepatitis A or hepatitis B vaccine 3 + 1; N = 1073 (N = 468 completed the follow-
up as specified in the protocol)
C2: hepatitis A or hepatitis B vaccine 2 + 1; N = 861 (N = 861 completed the follow-
up as specified in the protocol)
Additional vaccines: a combination vaccine containing diphtheria-tetanus-acellular per-
tussis-inactivated polio andHaemophilus influenzae type b (DTPa-IPV/Hib) and human
rotavirus vaccine were given at the same visit as the pneumococcal vaccine at 3 and 5
months. The DTPa-IPV/Hib vaccine was also co-administered at 11 to 12 months of
age
Outcomes Primary outcome - parent-reported, physician-confirmed all-cause AOM (stratified to
1 or more AOM episodes and overall AOM)
Secondary outcomes: parent-reported, physician-confirmed all-cause AOM with an-
tibiotic prescription (stratified to 1 or more AOM episodes and overall AOM), serious
adverse events occurring throughout the study period
Parents were asked by automatic text message every 2 weeks if their child had had a
physician-confirmed AOM diagnosis. If no contact could be made, AOM status was
checked at the next study visit
Funding sources GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of
the study conduct and analysis. GlaxoSmithKline Biologicals SA also took responsibility
for all costs associated with the development and publishing of this article
Declarations of interest Dr Vesikari declares that he received payment from the GlaxoSmithKline group of com-
panies and other vaccine manufacturers for board membership, consultancy, and attend-
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Vesikari 2016 (Continued)
ing meetings; the institution of Dr Kaijalainen received grants from the GlaxoSmithK-
line group of companies. 7 co-authors are employees of the GlaxoSmithKline group of
companies. Dr Hezareh is a consultant for Chiltern International for the GlaxoSmithK-
line group of companies. Dr Puumalainen was a GlaxoSmithKline group of companies
employee during the study. 4 co-authors declare stock and stock options ownership in
the GlaxoSmithKline group of companies, and 1 co-author declares shares ownership in
the GlaxoSmithKline group of companies. Dr Forsten and Dr Seppä declare no conflicts
of interest
Notes Participants lost to follow-up:total: 976/5093 (19.2%) did not complete the follow-
up period specified in the protocol
Participants lost to follow-up:Tx1: 0/1846 (0%) did not complete the follow-up period
specified in the protocol
Participants lost to follow-up:Tx2: 371/1313 (28.3%) did not complete the follow-
up period specified in the protocol
Participants lost to follow-up:C1: 605/1073 (56.4%) did not complete the follow-up
period specified in the protocol
Participants lost to follow-up:C2: 0/861 (0%) did not complete the follow-up period
specified in the protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Clusters were randomized (2:2:1:
1: PHiD-CV 3+1, PHiD-CV 2+1, control
3+1, control 2+1) using a blocking scheme,
stratified according to cluster size (below/
above average), urbanity (urban/rural), and
TampereUniversity Vaccine ResearchCen-
tre trial enrolment”
Allocation concealment (selection bias) Low risk Quote: “For nested study participants, in-
dividual randomization codes were used,
aligned with cluster randomization based
on place of residence”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated that thiswas a double-blind trial, but
no further details provided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Stated that thiswas a double-blind trial, but
no further details provided
Incomplete outcome data (attrition bias)
All outcomes
High risk Substantial number of participants not in-
cluded in analysis due to “randomization
error”
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Vesikari 2016 (Continued)
Selective reporting (reporting bias) Low risk Prespecified outcomes listed in clinicaltri-
als.gov/show/NCT00839254
Other bias Low risk No other sources of bias identified.
Ab: antibiotics
AOM: acute otitis media
C: control
CAP: community-acquired pneumonia
CRM197-PCV7: 7-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197
CRM197-PCV9: 9-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197
DCC: day-care centre
DTaP: diphtheria-tetanus toxoid-acellular pertussis vaccine
DTP: diphtheria-tetanus toxoid-pertussis vaccine
DTwP: diphtheria-tetanus toxoid-whole cell pertussis vaccine
ELISA: enzyme-linked immunosorbent assay
ENT: ear, nose, and throat
GP: general practitioner
HBV/placebo: hepatitis B virus vaccination plus placebo vaccine
Hib: Haemophilus influenzae type b
ICPC: International Classification of Primary Care
IgA: immunoglobulin A
IgG: immunoglobulin G
IPD: invasive pneumococcal disease
ITT: intention-to-treat
MenC: meningococcus type C conjugate vaccine
N: number
NaCl: sodium chloride
OM: otitis media
OMPC-PCV7: 7-valent pneumococcal conjugate vaccine conjugated to the outer membrane protein complex ofNeisseria meningitidis
serogroup B
PCR: polymerase chain reaction
PCV: pneumococcal conjugate vaccine
PHiD-CV10: 10-valent pneumococcal conjugate vaccine conjugated to protein D (surface lipoprotein of non-typeable Haemophilus
influenzae)
PHiD-CV11: 11-valent pneumococcal conjugate vaccine conjugated to protein D (surface lipoprotein of non-typeable Haemophilus
influenzae)
PPV23: 23-valent pneumococcal polysaccharide vaccine
RTI: respiratory tract infection
TIV: trivalent influenza vaccine
TIV/CRM197-PCV7: trivalent influenza vaccine plus 7-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197
TIV/placebo: trivalent influenza vaccine plus placebo vaccine
Tx: treatment
51Pneumococcal conjugate vaccines for preventing acute otitis media in children (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gisselsson-Solen 2011 No control vaccination
Jokinen 2012 Re-analysis of the Eskola 2001 study without new outcome data that could be used for our review
Le 2007 RCT studying the effect of PCV on OME
Palmu 2014 Secondary analysis of the FinIP trial, Palmu 2013, without outcome data that could be used for our review
Palmu 2015a Re-analysis of the Eskola 2001 study without new outcome data that could be used for our review
Palmu 2015b Secondary analysis of the FinIP trial, Palmu 2013, without outcome data that could be used for our review
Palmu 2018 Secondary analysis of the FinIP trial, Palmu 2013, without outcome data that could be used for our review
Roy 2011 RCT studying the effect of PCV on suppurative otitis media (abstract of conference meeting)
Sarasoja 2013 Re-analysis of the Eskola 2001 study without new outcome data that could be used for our review
OME: otitis media with effusion
PCV: pneumococcal conjugate vaccine
RCT: randomised controlled trial
A D D I T I O N A L T A B L E S
Table 1. Effect of pneumococcal conjugate vaccination on frequency of all-cause acute otitis media episodes
Intention-to-treat Per-protocol
Episodes/person-year In-
cidence rate
difference -
episodes per
person-year
(95% CI)
VE
expressed as
rel-
ative reduc-
tion in risk
(95% CI)a
Episodes/person-year Incidence
rate difference
- episodes per
person-year
(95% CI)
VE expressed
as relative re-
duction in risk
(95% CI)a
Treatment Control Treatment Control
PCV administered in early infancy
CRM197-PCV7
Black 2000
Fireman
2003
-
-
-
-
-
-
6% (4% to
9%)
6% (4% to
8%)
-
-
-
-
-
-
7% (4% to
10%)
7% (4% to
9%)
Eskola 2001 - - - - 1.16 1.24 −0.08d 6% (−4% to
16%)
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Table 1. Effect of pneumococcal conjugate vaccination on frequency of all-cause acute otitis media episodes (Continued)
O’Brien
2008b
1.43 1.36 0.07 (−0.05
to 0.18)
−5%
(−25% to
12%)c
1.35 1.35 0.00 (−0.13 to
0.14)
0% (−21% to
17%)
OMPC-PCV7
Kilpi 2003 - - - - - - - −1% (−12%
to 10%)
PHiD-PC10/11
Tregnaghi
2014
Sáez-Llorens
2017
0.03 0.04 −0.01 (−0.
01 to 0.00)
15% (−1%
to 28%)
- - - 13% (−5% to
28%)
Vesikari
2016b
- - - - 0.99 1.01 −0.02d 6% (−6% to
17%)
Prymula
2006
- - - - 0.08 0.13 −0.04d 34% (21% to
44%)
PCV administered at a later age
CRM197-PCV7 followed by PPV23
Veenhoven
2003
- - - −25%
(−57% to
1%)
1.1 0.83 −0.27d −29% (−62%
to −2%)
van Kempen
2006
- - - - 0.78 0.67 −0.11d −16% (−96%
to 31%)
CRM197-PCV7/TIV
Jansen 2008 - - - - - - - 57% (6% to
80%)e
CRM197-PCV9
Dagan 2001 - - - - 0.66 0.79 −0.14 (−0.29
to 0.02)
17% (−2% to
33%)
AOM: acute otitis media; CI: confidence interval; CRM197-PCV7: 7-valent pneumococcal conjugate vaccine conjugated to carrier
protein CRM197; CRM197-PCV7/TIV: trivalent influenza vaccine plus 7-valent pneumococcal conjugate vaccine conjugated
to carrier protein CRM197; CRM197-PCV9: 9-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197;
HBV: hepatitis B virus; OMPC-PCV7: 7-valent pneumococcal conjugate vaccine conjugated to the outer membrane protein
complex of Neisseria meningitidis serogroup B; PCV: pneumococcal conjugate vaccine; PHiD-CV10: 10-valent pneumococcal
conjugate vaccine conjugated to protein D (surface lipoprotein of non-typeable Haemophilus influenzae); PHiD-CV11: 11-valent
53Pneumococcal conjugate vaccines for preventing acute otitis media in children (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
pneumococcal conjugate vaccine conjugated to protein D (surface lipoprotein of non-typeable Haemophilus influenzae); PPV23:
23-valent pneumococcal polysaccharide vaccine; TIV: trivalent influenza vaccine; VE: vaccine efficacy
aPositive effect estimates indicates a relative reduction in the risk (e.g. 6% means that the vaccine reduces the risk by 6%); negative
effect estimates indicates a relative increase in the risk (e.g. −5% means that the vaccine increases the risk by 5%).
bCluster-randomised controlled trial.
cDefined as primary efficacy analysis. Analysis not entirely according to intention-to-treat principle, as 88/944 children were not
included in analysis due to not meeting strict chart review criteria.
d95% CI could not be calculated as person-time across treatment groups was not reported.
eIndex group: CRM197-PCV7/TIV, control: HBV/placebo; VE placebo/TIV versus HBV/placebo: 71% (95% CI 30% to 88%), i.e.
larger VE placebo/TIV versus HBV/placebo than CRM197-PCV7/TIV versus HBV/placebo.
Note: negative values for VE expressed as relative reduction in risk represent an increase in the risk for AOM.
Table 2. Effect of pneumococcal conjugate vaccination on frequency of pneumococcal acute otitis media episodes
Intention-to-treat Per-protocol
VE expressed as relative reduction in risk (95% CI) VE expressed as relative reduction in risk (95% CI)
Pneumo-
coccal
AOM
Vaccine-
type
AOM
Cross-
reactive-
type AOM
Non-
vaccine-
type AOM
Pneumo-
coccal
AOM
Vaccine-
type
AOM
Cross-
reactive-
type AOM
Non-
vaccine-
type AOM
PCV administered in infancy
CRM197-PCV7
Black 2000a
Fireman
2003
-
-
65% P = 0.
04
-
-
-
-
-
-
-
67% P = 0.
08
-
-
-
-
-
Eskola 2001
Palmu 2009
b
-
-
54% (41%
to 64%)
-
-
-
-
-
34% (21%
to 45%)
20% (7% to
31%)
57% (44%
to 67%)
-
51% (27%
to 67%)
-
−33%
(−80% to
1%)
-
O’Brien
2008a,c
- 64%
(−34% to
90%)
- - - - - -
OMPC-PCV7
Kilpi 2003 - - - - 25% (11%
to 37%)
56% (44%
to 66%)
−5%
(−47% to
25%)
−27%
(−70% to
6%)
PHiD-PC10/11
Tregnaghi
2014
Sáez-Llorens
53% (16%
to 74%)
70% (30%
to 87%)
29%
(−123% to
77%)
15%
(−153% to
71%)
56% (13%
to 78%)
67% (17%
to 87%)
26%
(−232% to
83%)
26%
(−231% to
83%)
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Table 2. Effect of pneumococcal conjugate vaccination on frequency of pneumococcal acute otitis media episodes (Continued)
2017
Vesikari
2016c
- - - - - - - -
Prymula
2006
- - - - 52% (37%
to 63%)
58% (41%
to 69%)
66% (22%
to 85%)
9% (−64%
to 49%)
PCV administered at a later age
CRM197-PCV7 followed by PPV23
Veenhoven
2003
- - - - 34% P = 0.
22
52% P = 0.
21
- 21% P = 0.
44
van Kempen
2006
- - - - - - - -
CRM197-PCV7/TIV
Jansen 2008 - - - - - - - -
CRM197-PCV9
Dagan 2001 - - - - - - - -
AOM: acute otitis media
CI: confidence interval
CRM197-PCV7: 7-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197
CRM197-PCV7/TIV: trivalent influenza vaccine plus 7-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197
CRM197-PCV9: 9-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197
MEF: middle ear fluid
OMPC-PCV7: 7-valent pneumococcal conjugate vaccine conjugated to the outer membrane protein complex ofNeisseria meningitidis
serogroup B
PCR: polymerase chain reaction
PCV: pneumococcal conjugate vaccine
PHiD-CV10: 10-valent pneumococcal conjugate vaccine conjugated to protein D (surface lipoprotein of non-typeable Haemophilus
influenzae)
PHiD-CV11: 11-valent pneumococcal conjugate vaccine conjugated to protein D (surface lipoprotein of non-typeable Haemophilus
influenzae)
PPV23: 23-valent pneumococcal polysaccharide vaccine
TIV: trivalent influenza vaccine
VE: vaccine efficacy
aMEF collected from spontaneous draining ears; in the other studies MEF was routinely collected during AOM episodes through
paracentesis.
bAdditional analysis of Eskola 2001 including pneumococcal AOM by a positive culture or PCR.
cCluster-randomised controlled trial.
Note: negative values represent an increase in the risk of AOM.
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Table 3. Effect of pneumococcal conjugate vaccination on frequency of recurrent acute otitis media
Intention-to-treat Per-protocol
VE expressed as relative reduction in risk
(95% CI)
VE expressed as relative reduction in risk
(95% CI)
PCV administered in infancy
CRM197-PCV7
Black 2000
Fireman 2003
9% (4 to 14)
10% (7 to 13)
9% (3 to 15)
-
Eskola 2001 9% (−12 to 27) 16% (−6 to 35)
O’Brien 2008a - -
OMPC-PCV7
Kilpi 2003 - -
PHiD-PC10/11
Tregnaghi 2014
Sáez-Llorens 2017
- -
Vesikari 2016a - -
Prymula 2006 - 56% (−2 to 81)
PCV administered at a later age
CRM197-PCV7 followed by PPV23
Veenhoven 2003 - -
van Kempen 2006 - -
CRM197-PCV7/TIV
Jansen 2008 - -
CRM197-PCV9
Dagan 2001 - -
CI: confidence interval
CRM197-PCV7: 7-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197
CRM197-PCV7/TIV: trivalent influenza vaccine plus 7-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197
CRM197-PCV9: 9-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197
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OMPC-PCV7: 7-valent pneumococcal conjugate vaccine conjugated to the outer membrane protein complex ofNeisseria meningitidis
serogroup B
PCV: pneumococcal conjugate vaccine
PHiD-CV10: 10-valent pneumococcal conjugate vaccine conjugated to protein D (surface lipoprotein of non-typeable Haemophilus
influenzae)
PHiD-CV11: 11-valent pneumococcal conjugate vaccine conjugated to protein D (surface lipoprotein of non-typeable Haemophilus
influenzae)
PPV23: 23-valent pneumococcal polysaccharide vaccine
TIV: trivalent influenza vaccine
VE: vaccine efficacy
aCluster-randomised controlled trial
Note: negative values represent an increase in the risk of recurrent AOM
Table 4. Adverse effects
Study ID No. of partici-
pants
PCV type Redness Swelling Pain/
tenderness
Fever Serious ad-
verse events
Black 2000/
Fireman 2003
37,868 CRM197-
PCV7
Depending on
timing
of dose, red-
ness occurred
in around
10% to 14%
of children re-
ceiv-
ing CRM197-
PCV7 ver-
sus 5% to 9%
of children re-
ceiving MenC
vaccination
More severe
redness (> 3
cm) occurred
in 0% to 0.6%
of children re-
ceiv-
ing CRM197-
PCV7 and did
not differ sig-
nificantly
from those re-
ceiving MenC
vaccination
Depending on
timing of
dose, swelling
occurred in
around
10% to 12%
of children re-
ceiv-
ing CRM197-
PCV7 ver-
sus 3% to 8%
of children re-
ceiving MenC
vaccination
More
severe swelling
(> 3 cm) oc-
curred in 0.
1% to 0.6%
of children re-
ceiv-
ing CRM197-
PCV7 and did
not differ sig-
nificantly
from those re-
ceiving MenC
vaccination
Depending on
timing
of dose, ten-
derness was re-
ported in 15%
to 23%
of children re-
ceiv-
ing CRM197-
PCV7 and did
not differ sig-
nificantly
from those re-
ceiving MenC
vaccination
Depending on
timing
of dose, fever >
38
°C occurred in
around
15% to 24%
of children re-
ceiv-
ing CRM197-
PCV7 versus
9% to 17%
of children re-
ceiving MenC
vaccination
Fever (> 39
°C) occurred
in 0.9% to 2.
5% of chil-
dren receiv-
ing CRM197-
PCV7 and did
not differ sig-
nificantly
from those re-
ceiving MenC
vaccination
No severe
adverse events
related to vac-
cination re-
sulting in hos-
pital-
isation, emer-
gency, or clinic
visits were re-
ported
Dagan 2001 264 CRM197-
PCV9
Depending on
timing
of dose, red-
Depending on
timing of
dose, swelling
Depending on
timing
of dose, ten-
Depending on
timing
of dose, fever >
Not reported
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Table 4. Adverse effects (Continued)
ness occurred
in 5% to 6%
of children re-
ceiv-
ing CRM197-
PCV9 ver-
sus 0% to 5%
of children re-
ceiving MenC
vaccination
occurred
in 7% to 12%
of children re-
ceiv-
ing CRM197-
PCV9 ver-
sus 0% to 5%
of children re-
ceiving MenC
vaccination
derness was re-
ported in 25%
to 38%
of children re-
ceiv-
ing CRM197-
PCV9 ver-
sus 0% to 8%
of children re-
ceiving MenC
vaccination
38
°C occurred in
around
15% to 44%
of children re-
ceiv-
ing CRM197-
PCV9 versus
8% to 25%
of children re-
ceiving MenC
vaccination
Fever (> 39.5
°C) oc-
curred in only
1 child receiv-
ing CRM197-
PCV9 versus
3 children re-
ceiving MenC
vaccination
Eskola 2001/
Palmu 2009
1662 CRM197-
PCV7
Depending on
timing
of dose, red-
ness occurred
in
14% to 20%
of children re-
ceiv-
ing CRM197-
PCV7
versus 9% to
16% of chil-
dren receiving
hepatitis vac-
cines
More severe
redness (> 2.5
cm) occurred
in 0% to 0.9%
of children re-
ceiv-
ing CRM197-
PCV7 and did
not differ sig-
nificantly
from those re-
Depending on
timing of
dose, swelling
occurred
in 5% to 6%
of children re-
ceiv-
ing CRM197-
PCV7 versus
2% to 6% of
children
receiving hep-
atitis vaccines
More
severe swelling
(> 2.5 cm) oc-
curred in 0.
5% to 1.3%
of children re-
ceiv-
ing CRM197-
PCV7 and did
not differ sig-
nificantly
from those re-
ceiving hep-
Depending on
tim-
ing of dose,
pain was re-
ported in 3%
to 8% of chil-
dren receiv-
ing CRM197-
PCV7 versus
2% to 3% of
children
receiving hep-
atitis vaccines
Fever (> 39
°C) occurred
in 0.4% to 2.
0% of chil-
dren receiv-
ing CRM197-
PCV7
versus 0.2% to
1.7% of chil-
dren receiving
hepatitis vac-
cines
No significant
differences be-
tween
vaccine groups
were ob-
served for un-
expected
events (6 ver-
sus 4 events)
1 child in
the CRM197-
PCV7 group
died from
bowel
obstruction,
necro-
sis, and shock
at the age of
8 months (85
days after ad-
ministration
of third dose),
but death was
as-
sessed as unre-
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Table 4. Adverse effects (Continued)
ceiving hep-
atitis vaccines
atitis vaccines lated to study
vaccine (au-
topsy revealed
mesenteric de-
fects
with volvulus
and other con-
genital abnor-
malities)
Jansen 2008 579 CRM197-
PCV7/TIV
- - - - Quote: “In
gen-
eral, the vac-
cinations were
well-tolerated,
and no imme-
diate or severe
adverse events
were recorded.
”
Kilpi 2003 1666 OMPC-
PCV7
OMPC-
PCV7 caused
local reactions
within 3 days
of each dose
more often
than the hepB
vaccine (data
not shown)
OMPC-
PCV7 caused
local reactions
within 3 days
of each dose
more often
than the hepB
vaccine (data
not shown)
Not reported Not reported There were no
statistically
significant dif-
ferences in the
occurrence
of any diagno-
sis among in-
dividu-
alswho experi-
enced serious
adverse events
between the 2
vaccine groups
1 child in the
OMPC-
PCV7 group
died
from volvulus
due to bowel
obstruction.
Death was as-
sessed as unre-
lated to study
vaccine
Prymula 2006 4968 PHiD-CV11 Not reported Not reported Not reported Not reported The per-
centages of
infants with
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Table 4. Adverse effects (Continued)
unsolicited
symptoms
that were
judged to
be causally
related to vac-
cination were
similar in the
PHiD-CV11
and hepA
group (2.5%
versus 3.0%)
. 14 serious
adverse events
were judged
to be causally
related to
vaccination:
8 occurred
in children
receiving
PHiD-CV11
vaccination
(7 after co-
administra-
tion with
Infanrix hexa
and 1 after
PHiD-CV11
booster) ver-
sus 6 in chil-
dren receiving
hepatitis
A control
vaccine (7
after co-ad-
ministration
with Infanrix
hexa and 1
after hepatitis
A booster
with Infanrix
hexa). All
events, apart
from 1 case
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Table 4. Adverse effects (Continued)
of epilepsy in
the hepatitis
A group,
resolved with-
out sequelae
4 chil-
dren died dur-
ing the study,
1 of which oc-
curred
in the PHiD-
CV11 group
(8 months af-
ter third dose,
diagno-
sis of epilepsy
was made; 25
months
after the third
dose the child
had grand mal
epilepsy
and died from
suffo-
cation). None
of the deaths
were regarded
by the inves-
tigators as re-
lated to the
study vaccine
Tregnaghi
2014/Sáez-
Llorens 2017
23,821 PHiD-CV10 Not reported Not reported Not reported Not reported Serious
adverse events
did
not differ sig-
nificantly be-
tween PHiD-
CV10 and
hepatitis con-
trol vaccines
(21.5% versus
22.6%). Only
1 event (in the
control group)
was judged to
be causally re-
lated to vacci-
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Table 4. Adverse effects (Continued)
nation by the
inves-
tigator, and it
resolved with-
out sequelae
19
children died
in the PHiD-
CV10 group
(0.16%) ver-
sus 26 in the
control group
(0.22%)
. None of the
deaths were
con-
sidered by the
investigator to
be causally re-
lated to vacci-
nation
Veenhoven
2003
383 CRM197-
PCV7
Not reported Not reported Not reported Not reported No serious ad-
verse events
were
noted after ad-
ministration
of CRM197-
PCV7 or hep-
atitis control
vaccines
Vesikari 2016 6178 PHiD-CV10 Not reported Not reported Not reported Not reported Se-
rious adverse
events consid-
ered by the
investigator to
be causally re-
lated to vac-
cination were
reported for 4
infants in the
PHiD-CV10
group (all in 3
+ 1 group: sep-
sis with non-
specified
aetiology in 1
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Table 4. Adverse effects (Continued)
infant, pyrexia
in 1 infant,
convulsion in
2 infants) and
for 2 infants in
HepB group
(petit mal
epilepsy in 1
infant
and pyrexia in
1 infant)
1 fatal serious
adverse event
(sudden infant
death, not
considered to
be vaccination
related)
was reported
in the PHiD-
CV10 (2 + 1)
group
C: Celcius
CRM197-PCV7: 7-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197
CRM197-PCV7/TIV: trivalent influenza vaccine plus 7-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197
CRM197-PCV9: 9-valent pneumococcal conjugate vaccine conjugated to carrier protein CRM197
hepB: hepatitis B
MenC: meningococcus type C
OMPC-PCV7: 7-valent pneumococcal conjugate vaccine conjugated to the outer membrane protein complex ofNeisseria meningitidis
serogroup B
PHiD-CV10: 10-valent pneumococcal conjugate vaccine conjugated to protein D (surface lipoprotein of non-typeable Haemophilus
influenzae)
PHiD-CV11: 11-valent pneumococcal conjugate vaccine conjugated to protein D (surface lipoprotein of non-typeable Haemophilus
influenzae)
TIV: trivalent influenza vaccine
63Pneumococcal conjugate vaccines for preventing acute otitis media in children (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Previous search details
For the 2014 version of the review we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 11),
which contains the Cochrane Acute Respiratory Infections Group’s Specialised Register; MEDLINE (1995 toNovember week 3, 2013);
Embase (1995 to December 2013); CINAHL (2007 to December 2013); LILACS (2007 to December 2013) and Web of Science
(2007 to December 2013).
We used the following search strategy to search CENTRAL and MEDLINE. We combined the MEDLINE search with the Cochrane
Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008
revision); Ovid format (Lefebvre 2011). We adapted the search strategy to search Embase, CINAHL, LILACS and Web of Science.
MEDLINE (Ovid)
1 exp Otitis Media/
2 otitis media.tw.
3 aom.tw.
4 or/1-3
5 Pneumococcal Vaccines/
6 Vaccines, Conjugate/
7 Bacterial Vaccines/
8 (pneumococc* adj5 (vaccin* or conjugat* or immuni*)).tw,nm.
9 pcv*.tw,nm.
10 or/5-9
11 4 and 10
For the 2009 version of the review we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library
2007, issue 2), which contains the Cochrane Acute Respiratory Infections Group’s Specialised Register; MEDLINE (January 1995 to
November 2007); and EMBASE (January 1995 to November 2007).
We used the following search strategy for searching MEDLINE and CENTRAL and modified terms for searching EMBASE.
MEDLINE
#1 explode ‘bacterial-vaccine’ / all subheadings
#2 explode ‘bacterial AND vaccine’ / all subheadings
#3 explode ‘Pneumococcus-vaccine’ / all subheadings
#4 pneumococc* near immunity*
#5 pneumococc* near vaccin*
#6 #1 or #2 or #3 or #4 or #5
#7 explode ‘otitis media’ / all subheadings
#8 (otitis media in ti) or (otitis media in ab)
#9 #7 or #8
#10 #6 or #9
#11 explode ‘randomised-controlled-trial’ / all subheadings
#12 explode ‘controlled-study’ / all subheadings
#13 explode ‘randomisation’ / all subheadings
#14 explode ‘single-blind-procedure’ / all subheadings
#15 explode ‘double-blind-procedure’ / all subheadings
#16 explode ‘crossover-procedure’ / all subheadings
#17 explode ‘phase-3-clinical-trial’ / all subheadings
#18 (control* near trial*) in ti)
#19 (control* near trial*) in ab)
#20 (singl* or doubl* or trebl* or tripl*) near ((blind* or mask*) in ti)
#21 (singl* or doubl* or trebl* or tripl*) near ((blind* or mask*) in ab)
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#22 random* near ((allocat* or assign*) in ti)
#23 random* near ((alsocat* or assign*) in ab)
#24 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25 #10 and #24
Appendix 2. MEDLINE (Ovid) search strategy
1 exp Otitis Media/
2 otitis media.tw.
3 (aom or om or ome or csom).tw.
4 glue ear.tw.
5 (otorrhea* or otorrhoea*).tw.
6 (middle ear adj5 (infect* or inflam* or effus*)).tw.
7 or/1-6
8 exp Pneumococcal Vaccines/
9 Vaccines, Conjugate/
10 Bacterial Vaccines/
11 (pneumococc* adj5 (vaccin* or conjugat* or immuni*)).tw,nm.
12 (pcv* or 5PPV* or 7PCV* or 9PCV* or 10PCV* or 11PCV* or 13PCV* or 15PCV* or synflorix).tw,nm.
13 or/8-12
14 7 and 13
Appendix 3. Embase (Elsevier) search strategy
#17. #12 AND #16
#16. #13 OR #14 OR #15
#15. random*:ab,ti OR placebo*:ab,ti OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR ’cross-over’:ab,ti OR volunteer*:
ab,ti OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/1 blind*):ab,ti
#14. ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#13. ’randomized controlled trial’/exp
#12. #6 AND #11
#11. #7 OR #8 OR #9 OR #10
#10. (pcv* or 5PPV* or 7PCV* or 9PCV* or 10PCV* or 11PCV* or 13PCV* or 15PCV* or synflorix):ab,ti,tn
#9. (pneumococc* NEAR/5 (vaccin* OR conjugat* OR immuni*)):ab,ti,tn
#8. ’bacterial vaccine’/de
#7. ’pneumococcus vaccine’/de
#6. #1 OR #2 OR #3 OR #4 OR #5
#5. (“middle ear” NEAR/5 (infect* OR inflam* OR effus*)):ab,ti
#4. otorrhea*:ab,ti OR otorrhoea*:ab,ti
#3. ’glue ear’:ab,ti
#2. ’otitis media’:ab,ti OR aom:ab,ti OR om:ab,ti OR ome:ab,ti OR csom:ab,ti
#1. ’otitis media’/exp
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Appendix 4. CINAHL (EBSCO) search strategy
S24 S14 and S23
S23 S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22
S22 (MH “Quantitative Studies”)
S21 (MH “Placebos”)
S20 TI placebo* OR AB placebo*
S19 TI random* OR AB random*
S18 TI ( singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl* mask*
) OR AB (singl* blind* or doubl* blind* or tripl* blind* or trebl* blind* or singl* mask* or doubl* mask* or tripl* mask* or trebl*
mask* )
S17 TI clinic* trial* OR AB clinic* trial*
S16 PT clinical trial
S15 (MH “Clinical Trials+”)
S14 S6 and S13
S13 S7 or S8 or S9 or S10 or S11 or S12
S12 (TI pcv* OR AB pcv* OR TI 5PPV* OR AB 5PPV* OR TI 7PCV* OR AB 7PCV* OR TI 9PCV* OR AB 9PCV* OR TI
10PCV* OR AB 10PCV* OR TI 11PCV* OR AB 11PCV* OR TI 13PCV* OR AB 13PCV* OR TI 15PCV* OR AB 15PCV* OR
TI synflorix OR AB synflorix)
S11 TI pneumococc* N5 immuni* OR AB pneumococc* N5 immuni*
S10 TI pneumococc* N5 conjugat* OR AB pneumococc* N5 conjugat*
S9 TI pneumococc* N5 vaccin* OR AB pneumococc* N5 vaccin*
S8 (MH “Bacterial Vaccines”)
S7 (MH “Pneumococcal Vaccine”)
S6 S1 or S2 or S3 or S4 or S5
S5 ((TI “middle ear” OR AB “middle ear”) N5 (TI infect* OR AB infect* OR TI inflam* OR AB inflam* ORTI effus* ORAB effus*))
S4 TI (otorrhea* or otorrhoea*) OR AB (otorrhea* or otorrhoea*)
S3 TI glue ear OR AB glue ear
S2 TI ( otitis media or aom or ome or csom) OR AB ( otitis media or aom or ome or csom)
S1 (MH “Otitis Media+”)
Appendix 5. LILACS (BIREME) search strategy
tw:((mh:“otitis media” OR “otitis media” OR “Otite Média” OR mh:c09.218.705.663* OR aom OR om OR ome OR csom OR
“glue ear” OR otorrhea* OR otorrhoea* OR (middle ear AND (infect* OR inflam* OR effus*))) AND (mh:“Pneumococcal Vaccines”
OR “Vacunas Neumococicas” OR “Vacinas Pneumocócicas” OR mh:“Vaccines, Conjugate” OR “Vacunas Conjugadas” OR “Vacinas
Conjugadas” OR mh:“Bacterial Vaccines” OR “Vacunas Bacterianas” OR “Vacinas Bacterianas” OR “pneumococcal vaccine” OR
“pneumococcal vaccines” OR “conjugate vaccines” OR “conjugate vaccine” OR pcv* OR 5ppv* OR 7pcv* OR 9pcv* OR 10pcv* OR
11pcv* OR 13pcv* OR 15pcv* OR synflorix)) AND (instance:“regional”) AND ( db:(“LILACS”))
Appendix 6. Web of Science (Clarivate Analytics) search strategy
# 5 113 #4 AND #3
Indexes=SCI-EXPANDED, CPCI-S, CCR-EXPANDED Timespan=2013-2018
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(Continued)
# 4 719,817 TOPIC: ((random* or placebo* or allocat* or crossover* or “cross over” or ((doubl* or singl*) NEAR/1 (blind* or
mask*)))) OR TITLE: (trial)
Indexes=SCI-EXPANDED, CPCI-S, CCR-EXPANDED Timespan=2013-2018
# 3 498 #2 AND #1
Indexes=SCI-EXPANDED, CPCI-S, CCR-EXPANDED Timespan=2013-2018
# 2 6,232 TOPIC: ((pneumococc* NEAR/5 (vaccin* or conjugat* or immuni*))) OR TOPIC: ((pcv* or 5PPV* or 7PCV* or
9PCV* or 10PCV* or 11PCV* or 13PCV* or 15PCV* or synflorix))
Indexes=SCI-EXPANDED, CPCI-S, CCR-EXPANDED Timespan=2013-2018
# 1 15,363 TOPIC: (“otitis media” or aom or om or ome or csom or “glue ear” or otorrhea* or otorrhoea* or (“middle ear”
NEAR/5 (infect* or inflam* or effus*)))
Indexes=SCI-EXPANDED, CPCI-S, CCR-EXPANDED Timespan=2013-2018
Appendix 7. ClinicalTrials.gov search strategy
(“otitis media” OR aom OR om OR ome OR csom OR “glue ear” OR otorrhea OR otorrhoea OR “middle ear infection” OR
“middle ear infections”) AND (pneumococcal OR pneumococcus) AND (vaccine OR vaccines OR vaccinating OR vaccination OR
vaccinations)
(“otitis media” OR aom OR om OR ome OR csom OR “glue ear” OR otorrhea OR otorrhoea OR “middle ear infection” OR “middle
ear infections”) AND (pneumococcal OR pneumococcus) AND (conjugate OR conjugated OR immunisation)
(“otitis media” OR aom OR om OR ome OR csom OR “glue ear” OR otorrhea OR otorrhoea OR “middle ear infection” OR “middle
ear infections”) AND (pneumococcal OR pneumococcus) AND (immunisations OR immunised OR immunising)
(Search has been split into 3 to work better on the ClinicalTrials.gov search portal)
Appendix 8. WHO ICTRP search strategy
pneumococc* AND vaccin* ANDotitis media OR pneumococc* AND conjugat* AND otitis media OR pneumococc* AND immuni*
AND otitis media OR pcv* AND otitis media OR pneumococc* AND vaccin* AND aom OR pneumococc* AND conjugat* AND
aom OR pneumococc* AND immuni* AND aom OR pcv* AND aom OR pneumococc* AND vaccin* AND middle ear infection*
OR pneumococc* AND conjugat* AND middle ear infection* OR pneumococc* AND immuni* AND middle ear infection* OR
pcv* AND middle ear infection*
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WH A T ’ S N E W
Date Event Description
29 March 2019 New citation required and conclusions have changed With this 2019 update, further information on the effect
of PHiD-CV10/11 for the prevention of acute otitis media
(AOM) has become available
Administration of the licenced CRM197-PCV7 and
PHiD-CV10 during early infancy is associated with large
relative risk reductions in pneumococcal AOM. However,
the effects of these vaccines on all-cause AOM is far more
uncertain. We found no evidence of a beneficial effect on
all-cause AOM of administering pneumococcal conjugate
vaccines (PCVs) in high-risk infants, after early infancy
(i.e. in children aged one year and above) and in older
children with a history of respiratory illness. Compared to
control vaccines, PCVs were associated with an increase
in mild local reactions (redness, swelling), fever, and pain/
tenderness, but we found no evidence of a difference in
more severe local reactions, fever, or serious adverse events
judged to be causally related to vaccination
29 March 2019 New search has been performed We updated the searches and included three new pub-
lications: two new randomised controlled trials (RCTs)
(Tregnaghi 2014; Vesikari 2016), and one new trial publi-
cation (Sáez-Llorens 2017), which reported outcome data
relevant for this review as part of a secondary analysis of
Tregnaghi 2014.
We excluded five new trial publications (secondary anal-
yses of previously included RCTs) (Palmu 2014; Palmu
2015a; Palmu 2015b; Palmu 2018; Sarasoja 2013), since
they did not report outcome data relevant to this review
We did not identify any ongoing studies.
The 14 included publications in this review originate
from 11 RCTs (60,733 children) in total: Black 2000/
Fireman 2003; Dagan 2001; Eskola 2001/Palmu 2009;
Jansen 2008; Kilpi 2003; O’Brien 2008; Prymula 2006;
Tregnaghi 2014/Sáez-Llorens 2017; van Kempen 2006;
Veenhoven 2003; Vesikari 2016.
Seven trials (59,415 children), Black 2000/Fireman 2003;
Eskola 2001/Palmu 2009; Kilpi 2003; O’Brien 2008;
Prymula 2006; Tregnaghi 2014/Sáez-Llorens 2017;
Vesikari 2016, included infants who predominantly re-
ceived primary vaccinations before six months of age
(Black 2000/Fireman 2003; Eskola 2001/Palmu 2009;
Kilpi 2003; O’Brien 2008; Prymula 2006; Tregnaghi
2014/Sáez-Llorens 2017; Vesikari 2016), while the other
four trials (1318 children), Dagan 2001; Jansen 2008; van
Kempen 2006; Veenhoven 2003, assessed the effects of
PCVs administered at a later age onAOMin either healthy
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infants, Dagan 2001, or in children with a history of respi-
ratory illness or frequent AOM(Jansen 2008; vanKempen
2006; Veenhoven 2003).
We added ’adverse effects’ as co-primary outcome.
H I S T O R Y
Protocol first published: Issue 2, 1999
Review first published: Issue 2, 2002
Date Event Description
21 February 2014 New search has been performed With this update, more precise information on the ef-
fect of PCV7 for the prevention of otitis media has be-
come available. We judged the quality of the evidence
for PCV7 in both early infancy and older children to
be high, with further research very unlikely to change
our confidence in the estimate of effect
Based on current evidence of the effects of pneumo-
coccal conjugate vaccines (PCVs) for preventing acute
otitis media (AOM), the licenced 7-valent PCV has
modest beneficial effects in healthy infants with a low
baseline risk of AOM. Administering PCV7 in high-
risk infants, after early infancy, and in older children
with a history of AOM appears to have no benefit in
preventing further episodes
Several randomised controlled trials (RCTs) with dif-
ferent (newly licensed, multivalent) PCVs adminis-
tered during early infancy to establish their effects on
AOM are currently ongoing. The results of these stud-
ies may provide a better understanding of the role of
the newly licenced, multivalent PCVs in preventing
AOM.Also, the impact of the carrier proteinD, as used
in certain pneumococcal vaccines for AOM, needs to
be further established
3 December 2013 New search has been performed Three new review authors joined the team to update
this review
The updated search (November 2007 to December
2013) retrieved 171 records. After removal of dupli-
cates 165 records remained. After full-text review, three
new publications (Palmu 2009; Prymula 2006; van
Kempen 2006) remained for inclusion. One study was
an additional analysis of the previous included Eskola
2001 study.
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We identified five ongoing RCTs (NCT00466947;
NCT00861380; NCT01545375; NCT01735084;
NCT01174849)
The 11 included studies in this review concerned a
total of nine RCTs: (1) Black 2000/Fireman 2003;
(2) Dagan 2001; (3) Eskola 2001/Palmu 2009; (4)
Kilpi 2003; (5) Prymula 2006; (6) van Kempen
2006; (7) Veenhoven 2003; (8) Jansen 2008; and (9)
O’Brien 2008. Five trials (Black 2000/Fireman 2003;
Eskola 2001/Palmu 2009; Kilpi 2003; O’Brien 2008;
Prymula 2006) (n = 47,108) included healthy infants
and studied the effect of PCV administered in early in-
fancy on otitis media (OM), while the other four trials
(n = 1318), Dagan 2001; Jansen 2008; van Kempen
2006; Veenhoven 2003, assessed the effects of PCV
administered at a later age on OM in either healthy in-
fants, Dagan 2001, or in childrenwith a knownhistory
of respiratory disease including OM (Jansen 2008; van
Kempen 2006; Veenhoven 2003).
29 April 2008 New citation required but conclusions have not
changed
New review authors
28 April 2008 Amended Converted to new review format
15 November 2007 New search has been performed Searches conducted
26 November 2003 New citation required and conclusions have changed Substantive amendment
29 June 2003 New search has been performed Searches conducted
19 August 2000 New search has been performed Searches conducted
C O N T R I B U T I O N S O F A U T H O R S
Alexandre C Fortanier and Roderick P Venekamp co-ordinated the review, were involved in data collection, and performed the ’Risk of
bias’ assessment and analysis and interpretation of the data. All review authors reviewed the manuscript and approved the final version
of the review.
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D E C L A R A T I O N S O F I N T E R E S T
Alexandre C Fortanier: in 2012, Alexandre C Fortanier was appointed as PhD student at the Julius Center for Health Sciences and
Primary Care, University Medical Center, University Utrecht, the Netherlands. This review is an integral part of his PhD programme.
Until 2017, Alexandre C Fortanier was employed by Janssen Vaccines &Prevention, Leiden, theNetherlands (formerly Crucell Holland
B.V.). Alexandre C Fortanier is currently an employee of Seqirus Netherlands B.V., Amsterdam, the Netherlands. Neither company
was involved in any aspect of the submitted work, nor did they act as a commercial sponsor of the review or his PhD programme. His
employer has no commercial or vested interest in the findings of this review and does not hold any patent relevant to the review.
Roderick P Venekamp is an Editor for Cochrane Acute Respiratory Infections and Cochrane ENT, but had no role in the editorial
process of this review.
Chantal WB Boonacker: none known.
Eelko Hak has authored a paper on the design of the CAPITA study (Netherlands Journal of Medicine), but was not involved in the
actual conduct of that study, nor does it pose a conflict of interest to the current work.
Anne GM Schilder: the evidENT team at University College London is supported in part by the National Institute for Health Research
(NIHR) University College LondonHospitals Biomedical ResearchCentre. Our research is funded by theNIHR and EUHorizon2020.
I am the national chair of the NIHR Clinical Research Network ENT Specialty. I am the Surgical Specialty Lead for ENT for the Royal
College of Surgeons of England’s Clinical Trials Initiative. I am co-investigator on the NIHR PGfAR grant ’Defining best Management
for Adults with Chronic RhinOsinusitis: the MACRO Programme’. In my role as director of the NIHR UCLH BRC Deafness and
Hearing Problems Theme, I act as an adviser on clinical trial design and delivery to a range of biotech companies.
Elisabeth AM Sanders: for research on pneumococcal vaccines, carriage and surveillance studies, Elisabeth AM Sanders received
money paid by governmental agencies and pharmaceutical companies GSK and Pfizer, and paid to the institution or collaborating
institutions. Furthermore, Elisabeth AM Sanders has participated in Independent Data Monitoring Committees and Advisory Boards
for pharmaceutical companies for vaccine studies and/or respiratory tract infections with fees paid to the institution before 2014. In
general, fees were always paid to the institution and used for research purposes.
Roger AMJ Damoiseaux: none known.
Elisabeth AM Sanders and Eelko Hak are authors of studies included in this review (Elisabeth AM Sanders: Jansen 2008; van Kempen
2006; Veenhoven 2003; Eelko Hak: Jansen 2008). To avoid any potential conflicts of interest, other review authors reviewed eligibility
and performed ’Risk of bias’ assessment and data extraction for these studies.
S O U R C E S O F S U P P O R T
Internal sources
• Department of Pediatric Immunology and Infectious Diseases, UMC Utrecht, Wilhelmina Children’s Hospital Utrecht,
Netherlands.
• Julius Center for Health Sciences and Primary Care, UMC Utrecht, the Netherlands, Netherlands.
• University Center for Pharmacy, PharmacoEpidemiology & PharmacoEconomics, University of Groningen, Netherlands.
• The National Institute for Public Health and the Environment, Biltoven, The Netherlands, Netherlands.
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External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Following feedback from a peer reviewer and editorial advice, we changed the title of this 2019 update to include the population
(children). We also added ’adverse effects’ as the co-primary outcome. We created a ’Summary of findings’ table for PCVs administered
in early infancy using the following outcomes: frequency of all-cause AOM episodes (co-primary outcome), adverse effects (co-primary
outcome), frequency of pneumococcal AOM, and frequency of recurrent AOM (defined as three or more AOM episodes in six months
or four ormore in one year). Furthermore, we used the five GRADE considerations (study limitations, consistency of effect, imprecision,
indirectness, and publication bias) to assess the quality of a body of evidence as it relates to the studies that contribute data to the
prespecified outcomes. This was not proposed in the protocol. Also, some (other) Cochrane methods have evolved over time. The
revised methods have been applied in the 2019 update where required.
N O T E S
The focus in research has shifted from the use of pneumococcal polysaccharide vaccines (PPVs) to pneumococcal conjugate vaccines
(PCVs) in children, and the role of PPVs in the prevention of AOM in children is not relevant anymore as PPVs are no longer used as
primary intervention in children since the introduction of PCVs. The focus of the current review has therefore shifted from the effect
of PPVs to the effect of PCVs on acute otitis media. No further attention will be paid to the effects of PPVs, which were described in
prior versions of this review (Straetemans 2003).
I N D E X T E R M S
Medical Subject Headings (MeSH)
AcuteDisease;OtitisMedia [microbiology; ∗prevention&control]; Pneumococcal Vaccines [∗therapeutic use]; RandomizedControlled
Trials as Topic; Vaccines, Conjugate [therapeutic use]
MeSH check words
Child; Child, Preschool; Humans; Infant
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